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ABSTRACT 
 
The Tbx1 gene encodes a transcription factor, TBX1, critical for heart 
development in several species, including humans. The haploinsufficiency of 
this gene is associated with DiGeorge Syndrome (DGS) named also 22q11.2 
Deletion Syndrome (22q11.2DS) which is characterized by multiple 
congenital anomalies, including heart disease (CHD). The molecular 
mechanisms by which TBX1 regulates its targets are unclear. In my thesis 
work I have focused on chromatin interactions mechanisms. In a first set of 
experiments using as a model a specific target gene, I have demonstrated that 
loss of TBX1 correlate with acetylation of a specific enhancer named anterior 
Heart Field (AHF) of the Mef2c gene, a gene critical for cardiogenesis. The 
mechanisms by which TBX1 affects histone acetylation need to be clarified, 
but we could not demonstrate a direct interaction with HDAC1 and HDAC2. 
Most of my thesis work has been dedicated to understanding the role of 
TBX1 in chromatin remodelling. By manipulation of two different model 
systems, I have generated maps of the accessible regions in different dosages 
of Tbx1. In P19Cl6 cells, I found that 86% of TBX1 binding sites are in 
closed chromatin. After Tbx1 knock down, I found that differentially 
accessible regions (DARs) are not localized in regions bound by TBX1. 
Consistent with this finding, I did not find T-box motifs in DARs. However, 
a limited study using time-course experiments identified a delayed chromatin 
remodelling in selected loci bound by TBX1. In contrast, a study of 
chromatin remodelling in differentiated murine embryonic stem cells 
(mESCs), WT and Tbx1-/- revealed that DARs do have T-box motifs 
suggesting that a good portion of chromatin changes may be located in 
TBX1-binding regions. Comparison between P19Cl6 and mESCs reveals 
differences about DARs binding motifs and communalities about the increase 
numbers of accessible regions after Tbx1 loss of function. In conclusion, my 
studies revealed new insight into the mechanisms by which TBX1 affects the 
chromatin landscape and indicate that mechanisms may be different 
depending on the cellular context. 
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ABBREVIATIONS 
 
 22q11.2 Deletion Syndrome  22q11.2DS 
 5-Azacytidine  5-Aza 
 acetylation of lysine 27 of histone 3  H3K27Ac 
 Adrenocorticotropic Hormone  ACTH 
 Anterior Heart Field  AHF 
 Assay for Transposase-Accessible Chromatin  ATAC 
 Atrial Siphon Muscle  ASM 
 Bone Morphogenetic Factor  BMF 
 Cardiac Progenitors  CP 
 Chromatin Immunoprecipitation  ChIP 
 Clustered Regularly Interspaced 
 Coloboma, Heart defects, Atresia chonae, Retarded growth, Genital 
hypoplasia, Ear anomalies  CHARGE 
 complementary Deoxyribonucleic acid  cDNA 
 Congenital Heart Defects  CHD 
 Deoxyribonucleic acid  DNA 
 Differentially Accessible Regions  DARs 
 Differentially Expressed  DE 
 DiGeorge Syndrome  DGS 
 Dimethyl sulfoxide  DMSO 
 epithelial-like layer of the SHF  eSHF 
 First Heart Field  FHF 
 Fluorescent Activated Cell Sorter  FACS 
 Gene Ontology  GO  
 Holt-Oram Syndrome  HOS 
 Hypergeometric Optimization of Motif Enrichment  HOMER 
 Knock-down  KD 
 Low Copy Repeat  LCR 
 Mitochondrial reads  M 
 monomethylation of lysine 4 of histone 3 H3K4me1  
 murine Embryonic Stem cells  mESC 
 Polymerase Chain Reaction  PCR 
 Prepulse Inhibition  PPI 
 Principal Component Analysis  PCA 
 Ribonucleic acid  RA 
 Second Heart Field  SHF 
 Serum Response Factor  SRF 
 small interfering RNA  siRNA 
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 Small Patella Syndrome  SPS 
 Spatial Clustered Identification of ChIP-Enriched Regions SICER 
 Systematic Evolution of Ligands by Exponential Enrichment  
SELEX 
 Transcriptional Start Site  TSS 
 Ulnar-Mammary Syndrome  UMS 
 Vascular Endothelial Grown Factor  VEGF 
 Velocardiofacial syndrome  VCFS 
 Ventricular Septal Defects  VSD 
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INTRODUCTION 
 
DiGeorge Syndrome and the candidate gene. 
 
The gene studied in the thesis work was identified in an effort to isolate the 
gene/s involved in DiGeorge syndrome (DGS) or 22q11.2 deletion syndrome 
(22q11.2DS) (Linsday EA et al., 2001; Merscher S et al., 2001). Congenital 
heart disease (CHD) affects 8/1000 live births. A common genetic cause of 
CHD is the 22q11.2 deletion, also known as DiGeorge syndrome (DGS) 
(McDonald-McGinn DM et al., 2015). It has been estimated that a substantial 
portion of patients with some specific heart defects have 22q11.2 deletions: 
52% of those with interrupted aortic arch type B, 34% with truncus 
arteriosus, 16% with tetralogy of Fallot and 5-10% with Ventricular Septal 
Defects (VSD). Besides CHD, patients have a number of other phenotypic 
features, for example cleft palate, development disabilities and schizophrenia. 
At the genetic level, the deletion could result from aberrant homologous 
recombination between low copy repeat (LCR) sequences, which flank the 
deleted regions (Edelman L et al., 1999). The name of this genetic disorders 
derives from Angelo DiGeorge who, in the late ‘60s, described this syndrome 
characterized by aberrant development of the thymus and parathyroid. Some 
of the development anomalies of DGS were also reproduced on chick models 
of neural crest ablation (Farrel MJ et al., 1999) leading investigators to 
hypothesize that DGS may derive from abnormal development of neural crest 
cell-contributed organs. However, more recent studies have implicated other 
cell lineages, specifically the cardiopharyngeal mesoderm, that will be 
discussed later. DGS is caused by chromosomal microdeletion of 
chromosome 22, at q11.2 locus; therefore, the disease is now commonly 
referred to as 22q11.2 deletion syndrome. Most patients with this syndrome 
have a large (3Mb) genomic deletion. About 10% of patients have a smaller 
deletion of about 1.5 Mb. Most genes localized in the region are conserved in 
the mouse on chromosome 16 (Gong W. et al., 1996; Botta A et al., 1997; 
Sutherland HF et al., 1998; Puech A et al., 1997; Lund J et al., 1999). This 
system allowed for the engineering of the first model, named Df1, which 
carries a deletion that encompasses mouse homologues of 18 genes that are 
deleted in patients with 1.5 Mb deletion whose phenotype is characterized by 
heart defects, thymus and parathyroid defects (Linsday EA et al., 1999). In 
particular, the cardiac defects may be rescued in Df1 mice on chromosome 
16 by reciprocal duplication (Dp1) on the homolog, restoring normal dosage 
of the Df1 region.  
Further mouse studies discovered that mutation of Tbx1, included in the Df1 
region, is sufficient to recapitulate the phenotypic spectrum of the disease 
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(Jerome LA et al., 2001; Linsday EA et al., 2001; Merscher S et al., 2001). 
The role of TBX1 in the human disease has been subsequently confirmed in 
human patients with clinical phenotypes consistent with DGS but lacking 
chromosomal deletions, but had mutations of TBX1 gene (Yagi H et al., 
2003). These studies demonstrated that heterozygous mutation of TBX1 is 
sufficient to cause most of the clinical features of 22q11.2DS patients. Tbx1 
mouse mutants show different phenotypes also seen in patients, for example: 
Tbx1-null mice have a small otocyst that fails to grow and does not give rise 
to the vestibular and cochlear apparata (Vitelli F et al., 2003). Auditory 
problems are common in 22q11.2DS patients (McDonald-McGinn DM et al., 
2015). In addition, loss of Tbx1 causes abnormalities of lymphatic vessel 
development as it regulates Vegfr3, a gene essential for lymphangiogenesis 
(Chen L et al., 2010). Lymphatic vessel defects have been found in 
22q11.2DS patients (Unolt M et al., 2018). 
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Tbx1 encodes a Transcription factor of the T-box family. 
 
The T-box family of transcription factors includes TBX2, TBX3, TBX4, 
TBX5, TBX6, TBX10, TBX13, TBX14, TBX15, TBX18, TBX19, TBX20, 
TBX21, TBX22, BRACHYURY, T-BRAIN1, EOMESODERMIN, and of 
course TBX1. These T-box proteins have a common DNA-binding motif 
called “T-domain” that binds DNA in a sequence-specific manner 
(Papaioannou VE, 2014). Genes encoding them have a vital role in 
embryogenesis and more recently they have also been implicated in cancer 
biology. The T-box binding element is a palindromic DNA sequence with 
strong affinity for BRACHYURY, also called as “T”, which interacts with 
that sequence in a dimeric form, each monomer binds a half site called T-half 
site (5’-AGGTGTGAAATT-3’) (Kispert A et al., 1993). The T-gene was 
discovered in 1927 because of a spontaneous mutation, which caused 
truncated tails in mice (Dobrovolskaia-Zavadskaia N et al., 1927).  
The T-box domain is about 180 amino acids long. The T-box domain, mostly 
situated in the middle portion of the protein, is a stretch of 180-190 aa 
residues and is defined as the minimal region that is necessary for the 
sequence-specific binding to DNA (Papaioannou VE et al., 1998). Different 
human genetic diseases are associated with mutations of T-box genes, for 
example mutation in Tbx3 causes an autosomal dominant disorder 
characterized by mammary gland hypoplasia, dental and genital 
abnormalities (Bamshad M et al., 1997; 1999) and upper limb malformations 
called Ulnar-Mammary Syndrome (UMS). Mutation in Tbx4 are associated 
with another genetic disorder named small patella syndrome (SPS) related to 
problem in skeletal development of patella (Bongers EM et al., 2004). 
Alteration in Tbx5 lead to an autosomal dominant disorder, Holt-Oram 
syndrome (HOS) in which most affected patients exhibit cardiac and limb 
malformations (Li QY et al., 1997). Finally, Yi et al., 1999 demonstrated that 
mutations of Tbx19 are associated with loss of adrenocorticotrophic hormone 
(ACTH) and melanocyte stimulating hormone in the corticotroph and 
melanotroph cell lineages in the pituitary resulting in adrenal insufficiency.  
T-box proteins have a variable weight: the range is from 50 to 78 kDa. 
Although, as described above, BRACHYURY binds DNA as a dimer 
(Papapetrou C et al., 1997) and exhibits a common human polymorphism 
Gly-177-Asp in the conserved DNA-binding domain, with each monomer 
binding half of the sequence, or T-half site (5’-AGGTGTGAAATT-3’). The 
T-box domains change between the different T-box proteins, although some 
specific residues are 100% conserved between the different T-box domains 
whose preference for different combinations of orientations, number and 
spacing of T-half sites may help to create binding specificity for target genes 
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(Conlon FL et al., 2001). The figure 1 shows a ribbon diagram of a human 
TBX3 monomer bound to its DNA target site. 
 
Fig. 1 
 
 
Figure 1. Structure of the TBX3/DNA Complex. Ribbon diagram of a human TBX3 
monomer bound to its DNA target site. Secondary structure elements are labelled, and 
helices, strands, and loops are depicted in turquoise, red, and grey, respectively (Coll M et 
al., 2002). 
 
After the discovery of the first Tbx1 mutations (Yagi H et al., 2003), 
additional patients have been described and two of them had a truncating 
mutation that resulted in loss of function due to the deletion of a C-terminal 
nuclear localization (Stoller JZ et al., 2005). Another missense mutation has 
been described in a familial case of Shprintzen syndrome. This missense 
mutation results in gain of function, possibly through stabilization of the 
protein dimer DNA complex (Zweier C et al., 2007). Prepulse inhibition 
(PPI) deficits in Df1/+ mice are caused by haploinsufficiency of Tbx1 and 
mutation in this gene is sufficient to cause reduced PPI (Paylor R et al., 
2006). Screening of TBX1 coding sequence identified a frameshift deletion 
(1320-1342del23bp) in patient with characteristic facial appearance of 
velocardiofacial (VCFS) and hypernasal speech (Paylor R et al., 2006). 
Overall very few Tbx1 mutations have been reported suggesting that they are 
rare. TBX1 binds to a consensus sequence that has been identified recently. 
Two studies have identified the consensus using different technologies: 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) 
(Castellanos R et al., 2014) and ChIP-seq (Fulcoli FG et al., 2016). TBX1 
preferentially binds to a tandem repeat of 5’-AGGTGTGAAGGTGTGA-3’ 
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but it can also interact with Half Sites. The figure 2 shows the motifs 
identified with SELEX (Tandem and Half site). 
 
 
 
Fig. 2 
 
 
Figure 2. Selection of specific oligonucleotides bound to TBX1. Sequence alignment 
shows that the optimal DNA binding motif for TBX1 is AGGTGT(G/T) (A/T) followed by 
two repeated similar motifs termed the Tandem Repeat (TR) and Half Site Partial Site as 
shown (½SPS) (Castellano R et al., 2014) 
 
De novo motif discovery, using ChIP-seq with a Tbx1 antibody, has 
uncovered an 8-bp consensus sequence (Fig. 3). 
 
Fig. 3 
 
 
Figure 3. TBX1 de novo motif. Sequence logo representing the enriched Tbx1 motif 
identified by de novo motif discovery (Fulcoli FG et al., 2016). 
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Table 1 lists the consensus sequences for a group of T-box proteins. 
 
Table 1 
Gene Publication Sequence Method 
Tbx1 Fulcoli FG et al., 2016 GG A G G/C T G G ChIP-
seq 
Tbx1 Castellanos R et al., 
2014 
A G G T G T G/T A/T SELEX 
Tbx5 Narlikar L  et al., 2013 GG/AA G G/A T G 
G/A 
ChIP-
seq 
Tbx5 Mori AD et al., 2006 A/G/T G/A G T G N 
N A 
ChIP-
seq 
Tbx5 Luna-Zurita L et al., 
2016 
G A G G T G ChIP-
EXO 
 
Table 1. DNA binding Motifs for T-box Transcription Factors identified with different 
techniques. The table is divided in Gene, Publication, Sequence and Method used (Baldini A 
et al., 2017). 
 
How does TBX1 bind DNA? The T-box domain of TBX1 is composed of a 
seven beta-barrel domain core related to an s-type immunoglobulin fold 
(Bork P et al., 1994), and closed by a smaller beta-pleated sheet as illustrated 
in the Fig. 4 (El Omari K et al., 2012). It has been proposed that TBX1 binds 
the DNA as monomer based on the observation that the molecular surface for 
potential dimerization is too small to be of biological significance. 
 
Fig. 4 
 
 
Figure 4. Structure of the TBX1/DNA Complex. Ribbon diagram of a TBX1 bound to its 
DNA target site. TBX1 is in yellow (monomer “a” light yellow, monomer “b” dark yellow), 
DNA is in blue) (El Omari K et al., 2012). 
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Tbx1 can regulate target genes without binding the DNA. 
 
DNA binding is not the unique mechanism by which Tbx1 can function.  
Two papers published in 2009 reported that TBX1 interacts with specific 
proteins and its biological function is independent from its binding to DNA. 
Fulcoli FG et al., 2009 have demonstrated an interaction between TBX1 and 
SMAD1. SMAD1 is a member of SMADS family of proteins that are key 
signal transducers downstream of the TGF-Beta superfamily type I receptors 
(Mehra A et al., 2000). SMAD1 has a central role in BMP signal transduction 
essential for mesoderm formation, cartilage development, postnatal bone 
formation and heart development. In addition, BMP4 plays an important role 
during gastrulation stage, in particular conditional deletion of BMPR1a in 
embryos showed a shortened cardiac outflow tract with septation defects, a 
process known to require neural crest and is necessary for perinatal viability 
(Stottmann RW et al., 2004). The interaction TBX1-SMAD1 suppresses 
SMAD1 binding to SMAD4, and a Tbx1 mutation that prevents binding to 
DNA does not affect binding to SMAD1 nor does it affect the ability to 
suppress SMAD1 activity (Fulcoli FG et al., 2009). Thus, TBX1 can affect 
the BMP signal transduction mechanism without binding the DNA. The 
TBX1-SMAD1 interaction is not the only mechanism by which TBX1 acts 
without binding to DNA. In another paper it has been shown that Tbx1 plays 
an important role in regulating proliferation and differentiation of multipotent 
heart progenitors by interacting with another transcription factor, Serum 
Response Factor (SRF), a master regulator of muscle differentiation, and it 
regulates negatively its level. The TBX1 effect on SRF dosage was not due to 
transcriptional downregulation but was proteasome-dependent (Chen L et al., 
2009). The TBX1-SRF interaction is potentially important for regulating the 
differentiation of cardiac progenitors (CP). Indeed, it was demonstrated that 
TBX1 promotes CP proliferation and inhibits their differentiation (Chen L et 
al., 2009). 
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Chromatin remodeling and Transcription factor activity. 
 
Although a systematic, unbiased screening of TBX1 protein interactions has 
not been done, an initial picture of TBX1-chromatin interactions is emerging. 
Many biological processes, in particular developmental programs, are 
controlled, by transcription factors and chromatin regulators. The cooperation 
between transcription factor and chromatin remodelers is necessary to 
maintain specific gene expression programs through epigenetic modification 
of the genome (Zaret KS et al., 2011). Thanks to new technologies it is 
becoming clear that there is a strong correlation between genome and epi-
genome. The epigenetic landscape of enhancer elements is important for 
commitment of embryonic stem cells and their self-renewal. There are at 
least two post-translational histone modifications correlated with TBX1 
known to date: H3K27Ac (the acetylation of lysine 27 of histone 3) and 
H3K4me1 (the monomethylation of lysine 4 of histone 3). H3K27Ac 
distinguishes active enhancers from primed ones, which are characterized 
only by H3K4me1 (Creighton MP et al., 2010). Chen et al., 2012, have 
demonstrated an interaction between TBX1 and a methyltransferase SETD7, 
but it has later been shown that this occurs outside from the chromatin 
context, so the significance of this interaction is unclear (Fulcoli FG et al., 
2016). In contrast, in the chromatin context, TBX1 interacts with KMT2C 
(MLL3). KMT2C and LSD1, a histone demethylase, maintain the 
methylation level of H3K4. ChIP-seq using anti TBX1 and H3K4me1 
antibodies revealed a highly significant overlap between TBX1 binding sites 
and H3K4me1-enriched regions. Furthermore, ChIP-seq with an antibody 
anti H3K27Ac demonstrated that TBX1 binds to H3K27Ac-poor regions 
(Fulcoli FG et al., 2016). Whether TBX1 actively maintains histone 
hypoacetylation is still unclear. ChIP-seq and RNA-seq correlations using 
P19Cl6 with and without Tbx1 knock down suggested that Tbx1 is neither a 
strong activator nor a strong repressor. In general, T-box proteins can be 
activators or repressors (Kawamura A et al., 2008), depending on biological 
context. For example, Tbx1 is “activator” for mechanisms correlated to 
proliferation and “repressor” for mechanisms correlated to differentiation of 
muscle cells (Chen et al., 2012). It is possible that the TBX1 function is to 
prime target enhancers and make them accessible to other regulators which 
can act as activator or repressor (Baldini A et al., 2017). It is possible that the 
Tbx1 haploinsufficiency phenotype could be a direct consequence of reduced 
H3K4me1, resulting in reduced accessibility of specific enhancers (Baldini A 
et al., 2017). 
TBX1 interacts also with ASH2l, the mammalian homolog of Drosophila 
ASH2 (absent small homeotic 2), a core component of multimeric histone 
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methyltransferase necessary for methylation of histone lysine residues. The 
interaction could be seen with a yeast 2-hybrid system and in mammalian 
cells, although its biological significance is unknown. (Stoller JZ et al., 
2010). TBX1 interacts also with Nkx2-5 which encodes a homeobox-
containing transcription factor required for heart development (Nowotschin S 
et al., 2006). Experiments in Ciona Intestinalis have revealed an antagonism 
mechanism between TBX1 and NKX2-5. Specifically, in cells undergoing 
asymmetric cell division of common progenitors, Nkx2-5 promotes GATA 
expression and cardiac specification in the second heart precursor by 
antagonizing Tbx1-mediated inhibition of GATA and activation of 
determinants of atrial siphon muscle (ASM) specification, the homologous 
regions of mastication muscle in mammalian (Wang W et al., 2013). 
Furthermore, it has been reported a genetic interaction between Chd7 and 
Tbx1, in particular it was found that these two genes were in epistatis and that 
the correct level of their expression was required in pharyngeal ectoderm for 
proper morphogenesis of the great arteries (Randall V et al., 2009). The Chd7 
gene encodes a chromo-domain containing, chromatin remodeling protein, 
involved in CHARGE syndrome (an acronym for Coloboma, Heart defect, 
Atresia choanae, Retarded growth, Genital hypoplasia, and Ear anomalies) 
which has some similarities with DGS. The mechanism of genetic interaction 
is unclear but CHD7 binds approximately 10000 regions in the mouse 
genome and most of them localize in H3K4me1 rich regions (Schnetz MP et 
al., 2010). This parallelism suggests that TBX1 and CHD7 may co-localize in 
some enhancers.  
Chen and co-workers (Chen L. et al., 2012) found an interaction between 
TBX1 and BAF60A also known as SMARCD1. This protein belongs to a 
SWI/SNF complex, whose members have helicase and ATPase activities and 
can regulate gene expression by remodelling chromatin (Hsiao PW et al., 
2003). TBX1 co-immunoprecipitates with BAF60A and is able to recruit 
BAF60A onto the target gene Wnt5a. Knock down of Baf60a affects the 
ability of TBX1 to regulate different target genes in vitro, including Wnt5a. 
Tbx1 and Wnt5a interact genetically because the loss of both genes produces 
a more severe phenotype than loss of one of them in vivo. In cultured cells, 
TBX1 binds the T-box binding elements of the Wnt5a gene (Chen et al., 
2012). It may be that TBX1 is able to interact with BAF60A and recruit the 
member of the complex in proximity to its target sites where it remodels 
chromatin and active target enhancers through recruiting of histone 
metyltransferase. Time-course experiments in vitro and expression analyses 
in vivo suggest that Baf60a is expressed in most tissues during mouse 
embryonic development and it is downregulated during cardiac 
differentiation. In contrast the expression of Baf60c (Smarcd3), an alternative 
member of the same complex, has an inverse correlation with cardiac 
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differentiation. Overall, the review of the literature presented here suggests 
that Tbx1 functions may be related to epigenetic modifications operated 
through interactions with other transcription factors, histone modifiers and 
chromatin remodelers.  
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Tbx1 and the Second Heart Field (SHF). 
 
Tbx1 expression is variable both spatially and temporally across tissues, it is 
expressed in mice during embryogenesis and is finely regulated (Xu H et al., 
2005). Specifically, it is expressed in the pharyngeal apparatus which 
includes phanyngeal endoderm, ectoderm, mesodermal core of pharyngeal 
arches, head mesenchyme and the second heart field (SHF) (Xu H et al., 
2005). The SHF is defined as a reservoir of cardiac progenitors, which 
gradually migrate into the heart and contribute to the growth of the outflow 
tract, the right ventricle and atria (Mjaatvedt CH et al., 2001; Kelly RG et al., 
2001; Waldo KL et al., 2001). The amniote heart is made up of 
cardiomyocytes arisen from two different adjacent progenitor cell 
populations in the early embryo (Meilhac SM et al., 2004). Early 
differentiating cardiac progenitor cells of the first heart field (FHF) give rise 
to the linear heart tube, that eventually becomes the left ventricle, and to part 
of the atria (Kelly RG 2012, Tzahor E et al., 2011). Progenitors of the SHF 
derive from the primitive streak and later localize to the pharyngeal and 
splanchnic mesoderm. These progenitors are multipotent and will give rise to 
cardiomyocytes and endothelial cells of the outflow tract, right ventricle and 
most of the atria (Kelly RG et al., 2001; Mjaatvedt CH et al., 2001). The SHF 
is divided into two subpopulations, the anterior and posterior SHF that 
contribute to the arterial and venous poles of the heart, respectively (De Bono 
C et al., 2018). SHF-derived segments of the heart share a lineage 
relationship with craniofacial skeletal muscle (Lescroart F et al., 2014) 
revealing that there are common progenitors that give rise to both cardiac and 
craniofacial muscle cells. This newly discovered lineage is conserved across 
species and has been named the cardiopharyngeal mesoderm (Diogo R et al., 
2015) (Fig. 5).  
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Fig. 5 
 
 
Figure 5. An evolutionary conserved cardiopharyngeal ontogenic motif. On the top, left: 
mouse embryo at E8 and 10, four chamber at E12 and mouse head at E14. On the top, right: 
Lineage tree depicting the origins of cardiac compartments and branchiomeric muscles in 
mice. All cells derive from common pan-cardiopharyngeal progenitors (dark green) that 
produce the FHF, precursors of the left ventricle and atria, and the second Tbx1+ 
cardiopharyngeal progenitors (light green). On the bottom, left: Cardiopharyngeal precursors 
in Ciona intestinalis hatching larva (left) and their derivatives in the metamorphosed juvenile 
(right). On the bottom, right: Lineage tree depicting clonal relationships and gene activities 
deployed in Ciona intestinalis cardiopharyngeal precursors. The latter pancardiopharyngeal 
progenitors express Nk4 and divide asymmetrically to produce the FHP (red) and second 
TVCs, the Tbx1/10+ second cardiopharyngeal progenitors (second TVC, light green disk) 
(Diogo R et al., 2015). 
 
Genetic experiments in mouse and other organisms have shown that Tbx1 is 
necessary for outflow tract development and it also affects the development 
of craniofacial muscle as well as other organs derived from the pharyngeal 
apparatus. Therefore, Tbx1 is hypothesized to be a major regulator of the 
development of the cardiopharyngeal mesoderm lineage. Genome-wide gene 
expression analysis in Tbx1 mutant embryos have highlighted a number of 
pathways that are affected by the loss of the gene. For example, in one study 
Hod and Nkx2-6 were downregulated in Tbx1 null embryos, in contrast some 
of the genes necessary for cardiac morphogenesis, such as Gata factors 
(Gata4), Raldh2 and Tbx5, and a subset of muscle genes were ectopically 
expressed (Liao J et al., 2008). Tbx1 also downregulates the expression of 
Vegfr2 in the posterior SHF and the expression of Vegfr2 is up regulated and 
extended in the absence of Tbx1 (Lania G et al., 2015). Tbx1 plays an 
important role for tissue architecture. Pathway analyses of Tbx1 target genes 
identified genes involved in focal adhesion and tissue architecture (Fulcoli 
FG et al., 2016). Recent data from the lab have confirmed that Tbx1 is 
required for the integrity of the axis ECM-Integrin-Focal adhesion in the SHF 
(Alfano D et al., 2018 Biorxiv). The communication between extracellular 
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matrix, integrin and focal adhesion, is altered in SHF of Tbx1 null mice, 
suggesting that Tbx1 is required for correct ECM-cell interactions. In 
particular, in the epithelial-like layer of the SHF (eSHF), Paxillin, Vinculin, 
E-cadherin, F-actin and NMIIB are mis-localized, possibly compromising the 
cohesiveness of the epithelial cell layer. Discoveries concerning the exact 
relationship between Tbx1 and SHF development will lead new insights into 
the pathogenesis of congenital heart defects.  
The developmental roles of Tbx1 has been under study for years. In Tbx1-null 
mice, outflow tract progenitor cells fail to expand and contribute to the dorsal 
pericardial wall and then to the heart poles, leading to abnormalities of the 
outflow and inflow tracts (Rana MS et al., 2014). The developmental roles of 
Tbx1 are at least partially conserved during evolution. For example, in 
zebrafish the loss of Tbx1 is associated with ventricular and outflow tract 
defects consistent with a conserved role in SHF-mediated cardiogenesis. 
More in details, in Tbx1 null animals there were 25% less cardiomyocytes 
that contributes to the heart tube suggesting a defective proliferation of 
cardiac precursor (Nevis K et al., 2013).  
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AIMS 
 
The overall aim of my thesis work is to explore mechanisms by which the 
transcription factor TBX1 regulates its targets through interaction with 
chromatin. 
In particular, I will address the following specific aims: 
 
1) To understand the relationship between TBX1 and histone 
acetylation. 
 
TBX1 binds H3K4me1-rich regions and H3K27Ac-poor regions. I will ask 
the question if TBX1 has an active role in maintaining the histone acetylation 
status on chromatin. To do this, I will use a cell culture model to understand 
if TBX1 dosage affects the acetylation status of the Mef2c “anterior heart 
field” enhancer.  
 
2) To map chromatin accessibility genome-wide with and without 
TBX1. 
 
I will use a recently developed technology, known as “Assay for 
Transposase-Accessible Chromatin followed by deep sequencing” (ATAC-
seq) to quantitatively measure chromatin accessibility genome-wide. I will 
use two cell models: mouse P19Cl6 cells and mouse embryonic stem cells 
(mESC). Both models can be differentiated in vitro. Manipulation of TBX1 
dosage will be obtained by small interfering RNA (for P19Cl6 cells) or by 
gene deletion (mESC). Finally, I will extend the experiments to genetically-
labelled cells purified from heterozygous and homozygous mutant mouse 
embryos. 
 
3) To determine the correlation between changes in chromatin 
accessibility and TBX1 binding to chromatin. 
 
I will integrate chromatin accessibility data with available map of TBX1 
binding sites and gene expression data. I will ask whether TBX1 has a local 
impact on chromatin remodelling and, if so, which genes respond to TBX1 
dosage changes. 
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MATERIALS AND METHODS 
 
1. Experimental Models 
 
 Mouse lines 
 
Tbx1Cre/+  
Cre-recombinase is knocked-into exon 5 of the Tbx1 gene. The insertion 
caused inactivation of the gene, so Tbx1Cre/+ animals are functionally 
heterozygous mutants (Huynh T et al., 2007). In this line, Cre is faithfully 
expressed in the Tbx1 expression domain. The Cre/loxP system has been used 
for many years in conditional mutagenesis in mice.  
 
R26RmT-mG 
This is a Cre recombination reporter line. Reporters of Cre enzyme are 
important for defining the spatial and temporal extent of Cre-mediated 
recombination. R26RmT-mG is a double-fluorescent Cre reporter mouse that 
expresses membrane-targeted tandem dimer Tomato (mT) in every tissue. 
Upon Cre-mediated recombination, it switches to expression of a membrane-
targeted green fluorescent protein (mG) (Muzumdar MD et al., 2007).  
 
Tbx1flox/+  
This line carries a loxP-flanked (flox) exon 5 of the Tbx1 gene (Xu et al., 
2004). Upon Cre recombination, the floxed allele is excised and the gene 
inactivated. 
Embryos with genotype Tbx1Cre/flox are functionally homozygous mutants but 
only in cells in which Tbx1 is expressed (and thus Cre is expressed). In 
embryos Tbx1Cre/flox; R26mT-mG, homozygous (recombined) cells are 
identifiable because they express green fluorescence. Mice were genotyped 
by PCR using DNA extracted from tail biopsies (or embryo yolk sacs) using 
the following primers pairs: 
 
 
Tbx1Cre: Tbx1Cre-F (5’-TGATGAGGTTCGCAAGAACC-3’) 
                Tbx1Cre-R (5’- CCATGAGTGAACGAACCTGG-3’) 
 
 
 
Tbx1flox: Tbx1flox-F (5’-CGACCCTTCTCTGGCTTATG-3’)  
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                 Tbx1flox-R (5’-AAAGACTCCTGCCCTTTTCC-3’) 
 
 
R26R mT-mG:  
 
  TOM R1 AAAGTCGCTCTGAGTTGTTAT  
  TOM R3 GGAGCGGGAGAAATGGATATG  
  pCAG GTCGTTGGGCGGTCAG 
 
PCR products were separated on 2% agarose gel. 
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 Cell lines (P19Cl6, C2C12, mESC) 
 
P19Cl6.  
P19Cl6 cells are a clonal derivative isolated from murine P19 embryonic 
carcinoma cells (Mueller I et al., 2010). This Cl6 subline efficiently 
differentiates into beating cardiomyocytes with adherent conditions when 
treated with 1 % DMSO. Cells are maintained a minimal essential medium 
supplemented with 10% fetal bovine serum, penicillin (100 U/mL), 
streptomycin (100 µg/mL) and L-glutamine (300 µg/mL). Cells were 
maintained at 37°C in 5% CO2.  
 
C2C12. 
C2C12 cells are mouse undifferentiated myoblast cells (ATCC CRL-1772) 
which express high levels of Tbx1 and can be manipulated through siRNA 
transfection. C2C12 were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Invitrogen) supplemented with 10% FBS and L-glutamine (300 
µg/mL). Cells were maintained at 37°C in 5% CO2. 
 
Mouse embryonic stem cells (mESC). 
Mouse embryonic stem cells (mESC) derive from the inner cell mass of 
blastocyst. Due to their ability to differentiate in many cell types, mESCs are 
largely used in the research lab for “in vitro” studies and it is a very powerful 
tool for genetic disease and obviously are extremely used in development and 
stemness field. We have used the line ES-E14TG2a (ATCC CRL-1821) that 
is grown in feeder free conditions. Cells were cultured in Glasgow medium 
(GMEM, Sigma), 15% FBS, ESGRO Chemicon (ESG1106), 100x β-
mercaptoethanol (BME), 100x Glutammine, 100x Non-Essential Amino Acid 
(NEAA), 100x Sodium pyruvate (NA-Pyr), 100x PenStrep. Cells were 
maintained at 37°C in 5% CO2. 
 
Gene knock down using small interfering RNA (siRNA). 
In P19Cl6 siRNA transfection, cells were plated at 5.0x105 per well in six-
well plates and transfected with a pool of Silencer Select Pre-Designed Tbx1 
siRNA (pool of s74767, s74768 and s74769, Life Technology) in antibiotic-
free medium using Lipofectamine RNA iMAX Reagent (Life Technology) 
according to the instructions. In ATAC-seq experiment, 42 hours after 
siRNA, using in the same time a siRNA control, cells were harvested and 
processed. In time course experiments, 13 hours after siRNA, using in the 
same time a siRNA control, cells were harvested and processed.  
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In C2C12 siRNA transfection, cells were plated at 1.2x105 per well in six-
well plates and transfected with a pool of Silencer Select Pre-Designed Tbx1 
siRNA (pool of s74767 and s74769, Life Technology) in antibiotic-free 
medium using Lipofectamine RNA iMAX Reagent (Life Technology) 
according to the manufacturer’s instructions. 48 hours after siRNA, using in 
the same time a siRNA control, cells were harvested and processed for 
further analyses. 
 
27 
 
 In vitro differentiation  
 
P19Cl6 
P19Cl6 cells differentiate into beating cardiomyocytes in adherent conditions 
when treated with 1% DMSO.  
The protocol used for this cells was established in the lab, and consists in 
plating about 500.000 cells in a 35-mm dish. Next day, when the cells are 
confluent, it was added 10uM 5-Azacytidine (5-Aza) to induce 
differentiation. After 24h, it was added a fresh medium containing DMSO 1 
%. For time course experiment for both loss and gain of function, cells were 
collected at T1 (13 hr after Transfection), at D1 (24 hr after 5-Aza induction) 
and at Day2 (24 hr after DMSO adding). 
 
mESCs  
mESCs differentiate into the cardiac lineage using a protocol established in 
Dr. Keller’s laboratory (Keller G 2005). This protocol generates, starting 
from undifferentiated embryonic stem cells, cardiac precursor (CP) and 
cardiomyocytes (CM). mESCs were maintained at Day 0 using leukemia 
inhibitory factor (LIF, 106 units/ml) when the cells were stimulated to 
proliferate as embryonic bodies by adding ascorbic acid (5 mg/mL) and 
monotioglycerol (MTG, dilution from 1.25 g/mL). At day 2, the 
differentiation can start by adding general growth factor: activin A (10 
ng/µL), bone morphogenetic factor (BMP4, 10 ng/µL), vascular endothelial 
growth factor (VEGF 5 ng/µL) while at day 4 starts the specification and 
maturation of cardiomyocytes by plating cells on gelatin coat with fibroblast 
growth factors (FGFb, 10 ng/µL; FGF10, 50 ng/µL) and VEGF (5 ng/µL), 
therefore day 4 cells encompass cardiac precursor markers. At day 10, cells 
become beating cardiomyocytes. The Fig. 6 illustrates the differentiation 
scheme. 
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Fig. 6 
 
 
Figure 6. murine Embryonic Stem Cells (mESCs) differentiation. Three different phases 
that mESCs need to differentiate into beating cardiomyocytes: Proliferation, Mesoderm 
induction, Endothelial/Cardiac specification and maturation (Keller G 2005). 
 
mESCs, differentiated at day 4, sorted for PDGFRa were isolated through 
flow cytometry. Tbx1-KO cells were generated in the lab using CRISPR-
Cas9 technology (Clustered regularly interspaced short palindromic repeats).  
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2. Molecular Biology procedures 
 
 RNA-seq 
 
Cells in dishes were washed with PBS cold and then 1 mL of Trizol was 
added directly on a single dish. Lysate was then harvested and vortexed in 
order to promote lysis of cells. Then, 200 µl of chloroform was added to 1 
mL in order to separate three distinct phases: upper phases (where we can 
find RNA), intermediated phases (where we can find DNA) and lower phases 
(where we can find proteins and other cells-derived). The mixture was 
centrifuged at 12000g for 15 min. The top (aqueous) phase was removed and 
transferred into a new tube in which was added 500 µl of isopropanol and the 
solution was incubated for 20 min at room temperature (RT). After 20 min, 
solution was centrifuged for 10 min at 12000g. Pellet (RNA) was washed two 
times with Ethanol 80% and centrifuged for 5 min at 7500 g. Pellet was 
resuspended in a fresh water and then processed for further analyses. The 
concentration was estimated with Nanodrop. All samples were run on 
agarose gel and all three different RNA fragments (28S, 18S and 5S) were 
distinguished. After quality/quantity check RNA samples were used for 
libraries preparation with the Illumina’s strand specific RNA seq protocol, 
barcoded and pooled in one lane. The raw data for sequencing of cDNA were 
generated with Illumina platform (NextSeq 500) for paired-end reads of 
length 75bp. 
 
30 
 
 Assay for Transposase-Accessible Chromatin (ATAC-seq) and 
quantitative ATAC (Q-ATAC) 
 
This new method, developed by Buenrostro et al., 2015 is now widely used 
for mapping chromatin accessibility genome-wide. This technique uses Tn5 
transposase which is able, when the chromatin is open, to insert sequencing 
adapters into accessible regions of chromatin. More in details, Tn5 is a 
prokaryotic transposase, which endogenously functions through the “cut and 
paste” mechanism, requiring sequence-specific excision of a locus containing 
19 bp inverted repeats. The Fig. 7 is a schematic representation of the 
technique. 
 
 
Fig. 7 
 
 
Figure 7. ATAC-seq schematic pipeline. Tn5 transposase (orange) insert sequencing 
adapters (green and red) in chromatin accessible regions. Open chromatin (violet) can be 
isolated, amplified and then sequenced (Buenrostro J et al., 2015). 
 
Sequencing adapters, associated to open chromatin regions, can be amplified 
and then sequenced. Sequencing adapters associated with regions of 
increased accessibility were recognized by Customer Nextera PCR Primer 1 
and Custom Nextera PCR primer 2 which contains barcode necessary for 
sample pooling. A complete list of primers is illustrated in the figure 8. 
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Fig. 8 
 
 
Figure 8. Custom Nextera PCR Primers. PCR primers are used to amplify fragment of 
opened chromatin. Primer 1 does not contain barcode while Primer 2 contains barcode 
necessary for sample pooling (Buenrostro J et al., 2015). 
 
It is possible to map regions of transcription factor binding and nucleosome 
position. ATAC-seq has replaced DNase-seq for open chromatin regions and 
MNase-seq for assaying nucleosome position because it is fast and sensitive. 
A critical point of this new technique is cells number: in general, too few 
cells causes over-digestion of chromatin and appears to create a larger 
fraction of reads that map to inaccessible regions of the genome; using too 
many cells may cause under-digestion and creates high molecular weight 
fragments, which certainly is difficult to sequence. Cells were harvested and 
they absolutely must not be fixed, intact cells in a homogenous suspension 
tend to give the best results. In order to determine the quantification of DNA 
obtained is not recommended Qubit analysis but we have used Tapestation, 
automated sample processing for quality control of Next Generation 
Sequencing and microarray data. 
For sequencing was used NextSeq 500, based on Illumina protocol, 60bp 
each reads in paired-end, MID flowcell, 240.000.000 total reads.  
ATAC-seq was optimized in about three hours: 30 minutes for nuclei 
extraction, 45 minutes for transposition and purification, 1 hour and 45 
minutes for PCR and purification and the remaining time for quantification 
analysis. More in details there are 4 main areas in which the protocol can be 
divided. The first one is cell preparation: we have used 50.000 cells for 
P19Cl6 cells and 12500 cells for mESCs. After washes in PBS, cells were 
suspended in 50 µL of cold lysis buffer (10mM Tris-HCl, pH 7.4, 10mM 
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NaCl, 3mM MgCl2, 0.1% IGEPAL CA-630) and immediately spin down at 
500 x g for 10 min at 4 °C. The second part consists of Transposition mix and 
Purification, the nuclei were incubated at 37 °C in Transposition Reaction 
Mix (25 µL reaction buffer, 2.5 µL of Transposase, 22.5 µL Nuclease free 
water), purified using Qiagen MinElute PCR Purification Kit and eluted in 10 
µL of Nuclease Free water. The Third part consists of PCR amplification of 
10 µL Tagmented DNA with 2.5 µL of PCR primer without barcode, 2.5 µL 
of specific barcode PCR primer, 10 µL Nuclease free water and 25 µL 
NEBNext High-Fidelity 2x PCR Master Mix. The PCR cycles are: 1 cycle of 
72°C for 5 min (critical to allow extension of both ends of the primer after 
transposition), 4 cycle of 98 °C for 10 secs, 63 °C for 30 secs and 72°C for 1 
min. In order to reduce GC and size bias in PCR, the appropriate number of 
PCR was calculated through real-time to stop amplification prior to saturation 
(Buenrostro J et al., 2013). The last part consists of assessing the 
quality/quantity of DNA purified which represent the regions of accessible 
chromatin.  
ATAC can be also associated to a screening, through real-time, of different 
loci in order to estimate how chromatin accessibility changes. This technique 
is called quantitative ATAC (Q-ATAC). In this work, Q-ATAC has done on 
a set of loci during loss and gain of function time-course experiments. 
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 Chromatin Immunoprecipitation (ChIP) and quantitative ChIP 
 
C2C12 cells were cross-linked with 1% formaldehyde for 15 min at room 
temperature and glycine was added to stop the reaction to a final 
concentration of 0.125 M for 5 min. The cell pellet was suspended in 6 x 
volumes of cell lysis buffer (10 mM HEPES, 60 mM KCl, 1 mM EDTA, 
0.075% v/v NP40, 1 mM DTT and 1X protease inhibitors, adjusted to pH 
7.6) in a 1.5 mL tube incubating on ice for 15 min. Isolated nuclei were 
suspended in Buffer B of LowCell ChIP Kit reagent and chromatin was 
sonicated into 200-500 bp long fragment using the Covaris S2 Sample 
Preparation System (Duty Cycle: 5%, Cycles: 5, Intensity: 3, Bath 
temperature: 4 °C. Cycles per Burst: 200, Power mode: Frequency Sweeping, 
Cycle Time: 60 seconds, Degassing mode: Continuous). After sonication, 
chromatin was diluted in Buffer A, according with LowCell Kit in order to 
make a SDS-dilution (SDS-high concentration may interfere between 
antibody and protein interaction). Chromatin was incubated with anti 
H3K27Ac (Abcam, ab4729), or normal rabbit IgG (Santa Cruz 
Biotechnology, 2027). Next, steps included extensive washes and reverse 
crosslinking following the same kit previously described. For quantitative 
ChIP, I performed real-time PCR of the immunoprecipitated DNA and 
inputs, using the FastStart Universal SYBR Green Master kit (Roche) on 
System or Step-one plus (Applied Biosystems) using primers specific for the 
AHF-enhancer region of Mef2c. 
 
Forward primer: TGAGGAGGGAGCTGCAGTAT 
Reverse primer: CCGTTTCTCTATCCCAACCA 
 
The experiment was performed two different Tbx1 dosages (Control and 
Tbx1-KD). The H3K27Ac around AHF-enhancer region was calculated on 
1% of input (sonicated and purified chromatin). Results are the mean of two 
biological replicates (error bars indicate s.e.m.). 
 
34 
 
 Antibodies 
 
All antibodies used for this Ph.D. project are listed in the Table 2. 
 
Table 2 
Group Antibody Code Secondary 
detecting 
Primary Anti-Histone H3 (acetyl 
K27) 
ab4729 VeriBlot 
(ab131366) 
Primary NF-YA sc-17753 Mouse 
monoclonal 
Primary HA 12CA5 Mouse 
monoclonal 
Primary Lamin B sc-6216 Goat 
polyclonal 
Primary B-actin A5316 Mouse 
monoclonal 
Primary IgG sc-2027 VeriBlot 
(ab131366) 
Secondary mouse IgG HRP linked NA931V -- 
Secondary rabbit IgG HRP linked NA934V -- 
Secondary goat IgG HRP linked SC-2020 -- 
 
Table 2. Antibody list used in this work. The table is divided in Group, Antibody, Code 
and    Secondary detecting. 
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3. Bioinformatics analyses 
 
 RNA-seq 
 
Two biological replicates were sequenced for each sample. For each 
replicate, we have used about 2.0 × 107, each read about 150bp long. Reads 
obtained were mapped to the mouse genome (mm9) using TopHAt2 
(Trapnell C et al., 2009). All other parameters were used as default. The 
reference annotation, Mus_musculus.NCBIM37.67.gtf, was downloaded 
from ensemble database (http://www.ensemble.org). Gene expression levels 
were estimated for each sample in term of Fragment Per Kilo base of exon 
model per Million mapped reads (FPKM) using Cufflinks (Trapnell C et al., 
2012). I selected only protein coding genes, all other proteins were masked 
from our analysis and for each gene we tested the significance of 95% 
confidence interval. For counting reads, I have used HT-seq (Anders S et al., 
2015) for gene count matrix and in order to pre-process RNA-seq data for 
differential expression analysis by counting the overlap of reads with genes. 
Then from this point I moved for further analysis with a graphical user 
interface (GUI) for the identification of differentially expressed genes across 
multiple biological condition, RNA-seqGUI (Russo F et al., 2014). This R 
package includes some well-known tools always used in the RNA-seq 
pipeline. All counted reads were normalized and for all data were plotted 
HeatMap Profiles and Principal Component Analysis (PCA) to establish the 
reproducibility in all experiments. At least, differentially expressed (DE) 
genes were estimated using DeSeq2 (Love MI et al., 2014) using default 
parameters. Gene with adjusted P-values < 0.05 were considered DE. 
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 ATAC-seq 
 
Although ATAC-seq is being adopted in many laboratories because is fast 
and sensitive, in literature there are no available pipelines. A new pipeline 
was developed in the lab in order to analyse these kind of data. First of all, 
each sample was sequenced in paired-end, 60 bp reads long. Quality check 
control on the raw sequencing data was made using FastaQC with different 
parameters: 1) Per base quality means how is it correct the position of each 
nucleotide in a read. This parameter is measured through a scale (0 is worst, 
36 is excellent); 2) GC content means how results, in the GC context, overlap 
with hypothetical distribution; 3) Per base N content means how many 
undefined nucleotides are calling; 4) Duplication levels means how many 
redundant reads are generated by PCR; 5) Adapter content means which is 
the percentage of adapters in selected reads.  
Reads were aligned using Bowtie2 (Langmead B et al., 2012). Bowtie2 is a 
tool for aligning sequencing reads to long reference sequences and it is used 
for reads of about 50 up to 100s or 1000s of characters. Analysis were 
performed using bash command from LINUX operative system and the 
output file was in Sam format.  
The Sam file stands for Sequence Alignment/Map format and it is a Tab-
delimited text format divided into two parts: the first one includes header and 
second one which has details about alignment, for example mapping position. 
A detailed example of Sam field output alignment is illustrated in the figure 9 
(Li H et al., 2009). 
 
Fig.9 
 
 
Figure 9. Sam output structure. Detailed field in Sam file are QNAME, FLAG, RNAME, 
POS, MAPQ, CIGAR, MRNM, MPOS, ISIZE, SEQ, QUAL (Li H et al., 2009). 
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FASTQC report, for all samples in our sequencing has found a short 
contamination around 33-35 bp to 47 bp of Nextera transposase sequence 
(black curve), figure 10. 
 
Fig. 10  
 
 
Figure 10. Adapter contamination in raw reads. On X-axis there is the position (bp), on Y-
axis the reads percentage. It is clearly visible Nextera Transposase Sequence contamination 
between 33-35 and 47 bp (black curve). 
 
Nextera Transposase Sequence were removed in order to increase the 
alignment rate output. The “contaminations” sequences were 
CTGTCTCTTATACACATCTCCGAGCCCACGAGAC which is the reverse 
complement of the Nextera transposase sequence attached to read 2 and 
CTGTCTCTTATACACATCTGACGCTGCCGACGA which is the reverse 
complement of the Nextera transposase sequence attached to read 1 (Turner 
FS et al., 2014). Cutadapt was used to remove the Nextera transposase 
sequences. This algorithm is largely used in bioinformatics analysis, it 
searches and cut off specific sequence independent from its localization 
(Martin M 2011). Reads without Nextera transposase sequences are 
illustrated in the figure 11. 
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Fig. 11 
 
 
Figure 11. Contamination free in raw reads. On X-axis there is the position (bp), on Y-axis 
the reads percentage. Nextera Transposase Sequence was completely removed. 
 
Once files in Sam format with uncontaminated reads were obtained, they 
were converted into Bam files and then in Bed files. Bam file is the 
compressed binary version of a Sam file that is used to represent aligned 
sequences. It is divided into Header which contains general information: 
sample name and length, the alignment method, start/end position, alignment 
quality and the match descriptor string. Furthermore, the alignment section 
includes the following information: RG (number of reads for specific 
sample), BC (indicate demultiplexed sample ID associated with the read), 
SM (single-end alignment quality), AS (paired end alignment quality), NM 
(Edit distance tag), XN (Amplicon name tag) (Li H. et al., 2009).  
Bed format stand for Browser Extensible Data and it can be defined as a 
flexible way to represent genomic coordinates in a very sample manner. In 
Bed file there are different parameters: chromosome (the name of the 
chromosome on which the genomic feature exists), start (the zero-based 
starting position of the features in the chromosome), end (the one-based 
ending position of the feature in the chromosome). Then there are other 
optional columns, for example: name (the name of the Bed feature), score 
(Bed score range between 0 to 1000), strand (defines the strand “+” or “–”) 
(Quinlan AR et al., 2010). From file Bed, R1 and R2 reads (sequencing was 
made in paired-end mode) were isolated using “grep” as bash command and 
then sorted using bedtools. Starting from Bed files, it was calculated files 
which contain all genomic coordinates without PCR duplicates. Last problem 
in ATAC-seq technique was linked to mitochondrial reads (M) that can 
strongly reduce number of reads. There is one literature study which explain 
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a possible method to reduce mitochondrial reads using CRISPR-CAS9. 
Researchers, through CRISPR, were able to reduce mitochondrial noise from 
samples by 1.5 to 3 fold (Montefiori L et al., 2017). Mitochondrial reads 
were counted and removed from files and used for genome coverage and at 
least they were uploaded on UCSC Genome Browser. 
The last bioinformatics analysis was peak calling, which quantify how many 
open regions (peaks) were there in a specific sample. The algorithm used is 
MACS2 (Model-Based Analysis of ChIP-seq), has been optimized for ChIP-
seq and DNase-seq data but it is largely used in the ATAC-seq work (Feng J 
et al., 2012). This tool identifies statistically enriched genomic regions. By 
default, it is able to calculate also PCR duplicates by removing them and 
calculates also a p-value for each peak using a dynamic Poisson distribution 
to capture local bias in read background levels. In ATAC-seq, due to absence 
of input sample, MACS2 measures the total genome-wide coverage 
background in order to estimate enriched accessible regions. The bash 
command used was: /share/apps/MACS2-2.1.1/bin/macs2 callpeak -t 
file_input.bed -f BED -g mm -n file_output.bed -nomodel --shif100 --extsize 
200.  /share/apps/MACS2-2.1.1/bin/ represents the directory path in which 
MACS is located; macs2 was the version used; -t recalls the input file; -f 
specifies the file input type; -g is the animal genome (mm9 in our analyses); 
shift and extsize represent some advanced parameters which consider the Tn5 
transposase cut site. 
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 Real-time PCR, statistical analysis 
 
Real-time polymerase chain reaction, also known as quantitative real time 
polymerase chain reaction (qPCR) or kinetic polymerase chain reaction, is a 
molecular technique based on PCR, which is used to amplify and quantify a 
targeted DNA molecule. It enables both detection and quantification (as 
absolute number of copies or relative amount when normalized to DNA input 
or additional normalizing genes) of a specific sequence in a DNA sample. 
RNA was extracted from cells using Trizol reagent (explained in more details 
in the session “RNA-seq”). Before reverse transcription, RNA samples were 
treated with DNAse I. Contamination with genomic DNA (located in the 
interphase during trizol extraction) was identified by including “no RT/RT- 
controls”. cDNA was retro-transcribed from 1 to 2 µg of RNA. All samples 
were run in duplicates in 15 µL reaction volume. The run used was similar to 
PCR default condition but the number of cycles is increases up to 45 cycles. 
The cycle threshold (Ct) was determined during geometric phase of the PCR 
amplification plots, as illustrated in the manufacturer. Relative differences in 
transcript levels were quantified using the ΔΔCt method and normalized to 
Gapdh and Rpl13a expression references. The Tbx1 primers were: 
 
Forward: 5'-CTGACCAATAACCTGCTGGATGA-3' 
Reverse: 5'- GGCTGATATCTGtGCATGGAGTT-3' 
 
For time-course experiments with loss of function (LoF) and gain of function 
(GoF) they were set different statistical parameter in order to understand if 
there are chromatin accessible variations between control and treated samples 
on some specific loci (Q-ATAC). It was calculated 2- ΔCt by considering the 
differences between Ct of sample and Ct of endogenous control. It was 
added, as internal control, the DNA extracted from the same undifferentiated 
cell lines (P19Cl6) in order to minimize the differences in primers annealing 
efficiency. 
Biological duplicates were considered and for each sample it was measured 
the standard deviations and error standard in order to assess whether each 
locus has or not variations in chromatin accessibility between samples. 
Negative control was used to establish the threshold of opened/closed 
chromatin. Primers were designed in a region that does not contain genes for 
about 80 kb. The Ct signal of this genomic window was set as the threshold: 
trend above threshold has indicated as “open chromatin”; in contrast, trend 
below threshold has indicated as “closed chromatin”. 
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RESULTS 
 
Chapter 1 
TBX1 controls histone acetylation at the Mef2c-Anterior Heart Field 
(AHF) locus. 
 
TBX1, in P19Cl6 cells, tends to coincide with H3K27Ac-poor regions 
(Fulcoli FG et al., 2016). In order to explain why TBX1 tends to bind hypo-
acetylated regions, the mechanism remains unknown. TBX1 binds to and 
represses Mef2c expression (Pane LS et al., 2012), therefore, we used this 
gene as a model to understand mechanisms of gene regulation. TBX1 binds 
the so called “anterior heart field” (AHF) enhancer of Mef2c gene. To 
understand if this enhancer could be differentially acetylated following by 
Tbx1 dosage variation, we performed a Chromatin Immunoprecipitation 
(ChIP) with anti H3K27Ac antibody on undifferentiated C2C12 cells (see 
Materials and Methods paragraph for further informations) with and without 
Tbx1 knock down using transfection with siRNA pool (Fig. 12).  
 
Fig. 12 
 
 
 
Figure 12. Tbx1-KD in C2C12 cells. Tbx1 (239bp) was knocked down in C2C12 cells on 
three different biological replicates (Tbx1-KD_1, Tbx1-KD_2, Tbx1-KD_3) compared to 
control (Control_1, Control_2, Control_3). Gapdh (106bp) was used as control. 
 
I have chosen the first and second replicate because the transfection was 
better than third biological replicate and then it was performed ChIP with 
H3K27Ac followed by real-time PCR on AHF enhancer. I found that C2C12 
with low level of Tbx1 have a significant increase of H3K27Ac enrichment at 
the Mef2c-AHF enhancer compared to Control (Fig. 13) suggesting that 
TBX1 is able to maintain H3K27Ac enrichment low. The H3K27Ac 
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enrichment of Mef2c-AHF has been calculated on two biological duplicates 
and immunoprecipitation (expressed in percentage) was based on 1% DNA 
input from the same cell line. Colleagues in the lab have tested whether 
TBX1 interacts with HDAC1 or HDAC2, but with negative results. Thus, 
decreased dosage of TBX1 is associated with increased H3K27Ac, but the 
mechanism by which low acetylation is maintained by TBX1 is probably 
indirect. These results have been included in a publication (Pane LS et al., 
2018). Future experiments will explore the relationship between TBX1 
dosage and H3K27Ac genome-wide using ChIP-seq. 
  
Fig. 13 
 
 
Figure 13. TBX1 and H3K27Ac enrichment at Mef2c-AHF enhancer in C2C12 cells. 
Histogram showing the results of Q-ChIP analyses using anti H3K27Ac antibodies on 
C2C12 cells treated with non-targeting siRNA (Control) or with Tbx1-targeted siRNA 
(Tbx1-KD) on Mef2c-AHF locus. Enrichment is shown as percentage of input. Results are 
the mean of two biological replicates (error bars indicate s.e.m.). 
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Chapter 2 
 
Generation of chromatin accessibility maps of P19Cl6 cells with and 
without Tbx1. 
 
To generate maps of chromatin accessibility, we started with P19Cl6 cells. 
The choice of P19Cl6 model system was due to the availability of TBX1 
binding sites map previously generated on the same model. Starting from 
published TBX1 ChIP-seq data (Fulcoli FG et al., 2016) and then compared 
them to new ATAC-seq data, we have tried to comprehend how chromatin 
variations change where TBX1 binds chromatin. Principal Component 
Analysis (PCA) of P19Cl6 transcriptional profile and differentiated mouse 
embryonic stem cells (mESCs) established that P19Cl6 differentiated at Day 
1, with highest Tbx1 expression, have a transcriptional profile intermediate 
between ESC and mesodermal differentiation states (Fulcoli FG et al., 2016) 
therefore this time-point mimics what happen in mouse model during Tbx1 
expression. I started experiments through manipulation and differentiation of 
P19Cl6 cells by culturing cells and after one passage, cells were transfected 
using a pool of Tbx1 small interference RNA (siRNA). About 5.0 x 105 cells 
were seeded in the 35mm dishes and it was used 25 pmol of siRNA 
conjugated with Lipofectamine (RNAimax). 18hr after transfection, cells 
were induced with 5-Azacytidine (5-Aza, is an analogue of cytidine that 
cannot be methylated). Once added 5-Aza to cell culture medium, cells start 
to differentiate in the cardiac cells lineage. Under 5-Aza addition, P19Cl6 
showed the highest Tbx1 expression. After 24hr from 5-Aza induction, cells 
were collected and processed for analysis. The protocol of P19Cl6 
differentiation is illustrated in the figure 14. 
 
Fig. 14 
 
 
Figure 14. P19Cl6 cells differentiation until D1. The differentiation scheme starts from 
transfection point (siRNA). 18 hours after transfection, cells were induced with 5-Aza and 
collected 24 hours later at D1. 
 
Cells were collected (two biological duplicates for each conditions: Control 
and Tbx1-KD) exactly after 24hr from 5-Aza induction and 50.000 cells were 
processed for ATAC while all the others were used for RNA extraction. The 
44 
 
DNA tagmented with Tn5 enzyme was stored at -20 °C until transfection 
evaluation. The RNA was extracted and checked for quality was verified 
using a 1.5% agarose gel. About 1.5 microgram of RNA was uploaded on 
gel. The results illustrated in the figure 15 suggested that quality was good 
because bands of 28S, 18S and 5S were visible.  
 
Fig. 15 
 
       Control   Tbx1-KD 
 
Figure 15. P19Cl6 RNA quality. RNA extracted from P19Cl6 was uploaded on 1.5 % 
agarose gel. Bands of 28S, 18S and 5S were detectable. 
 
Once assessed the quality and quantity with NanoDrop fluorimeter of RNA, 
1µg was retrotranscribed into cDNA and Tbx1 expression levels were 
measured using real-time PCR using technical triplicates (Fig. 16). As 
normalizer we used Gapdh gene expression. 
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Fig. 16 
 
 
Figure 16. Tbx1-KD in P19Cl6 cells. Tbx1 was reduced of 88% in KD sample compared to 
Control. All samples were in technical triplicates. RQ expresses the normalized expression 
value. 
 
I obtained a reduction of Tbx1 expression level of about 90% compared to 
Control. After KD evaluation, tagmented samples, previously stored at -20 
°C, were used for PCR amplification. Amplified DNA was then purified, the 
fragment size and concentration were estimated using a Tapestation 
instrument which is able to quantify the double strand DNA concentration 
and size distribution during electrophoresis assay. The figure 17 shows 
details of the tapestation output. On the X-axis is indicated the sample 
fragment size while on Y-axis there is a relative measure of DNA quantity. 
 
Fig. 17 
       Control-1 
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     Tbx1-KD-1 
 
 
     Control-2 
 
 
      Tbx1-KD-2 
 
 
Figure 17. DNA concentration and size distribution in P19Cl6 cells. On the X-axis is 
indicated the sample fragment size while on Y-axis there is a relative measure of DNA 
quantity. Electrophoresis assay were estimated for Control-1, Control-2, Tbx1-KD-1 and 
Tbx1-KD-2.  
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The two biological replicates for both conditions were sequenced based on 
fragment distribution reported in figure 17. The sequencing was done using 
NextSeq 500, based on Illumina protocol, 60bp each reads in paired-end, 
MID flowcell, 240.000.000 total reads. The ATAC-seq pipeline has been 
described in the Materials and Methods section. I describe some additional 
details concerning the P19Cl6 experiment. First of all, I have examined the 
number of raw reads from each biological replicate. All 4 samples (Control 
and Tbx1-KD in biological duplicates) were sequenced in a single flow cell 
and the number of reads for each sample was: 25373112 for Control (first 
replicate), 63880623 for Control (second replicate), 33998199 for Tbx1-KD 
(first replicate) and 65812087 for Tbx1-KD (second replicate). Before 
mapping with reference genome, I evaluated the sequencing quality of all 
samples. The first replicate for both conditions was bad because more than 
half reads were PCR duplication artefacts. However, I decided to continue 
analyses. The second problem was removing the Nextera transposase 
sequence because the presence of adapters contamination could alter 
alignment between reads and reference genome. We aligned before and after 
Nextera transposase sequence and we found an improvement of alignment 
rate in the reads without Nextera transposase sequence (Table 3).  
 
Table 3 
Sample Reads with Nextera 
transposase sequence 
Reads without Nextera 
transposase sequence 
Control-1 71.68% 89.59% 
Tbx1-KD-1 44.24% 49.52% 
Control-2 84.29% 96.26% 
Tbx1-KD-2 41.62% 44.72% 
 
Table 3. Alignment rate (%) before and after removing of Nextera transposase sequence 
in    P19Cl6 cells. The table is divided in Sample, Reads with Nextera transposase Sequence 
and Reads without Nextera transposase Sequence). 
 
By removing Nextera transposase Sequence, I found an alignment 
improvement of 17.88% for Control and 11.97% for Tbx1-KD for the first 
replicate. For second replicate there was an improvement of 5.28% for 
Control and 3.1% for Tbx1-KD. Then I moved to mitochondrial reads (M) 
calculation and removing them from samples. The table 4 illustrates for each 
sample how many reads were found and the effective reads used for genome 
coverage and peak calling (Reads after M depletion).  
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Table 4 
Sample Reads 
before M 
depletion 
Mitochondrial 
Reads 
Reads 
after M 
depletion 
Control-1 3289151 56757 3226394 
Tbx1-KD-1 16022976 1040265 14982711 
Control -2 12394516 959542 11434971 
Tbx1-KD-2 12299146 1090975 11208171 
 
Table 4. Comparison between the number of total reads with and without 
Mitochondrial reads in P19Cl6 cells. The table is divided in Sample, Reads before M 
depletion, Mitochondrial Reads and Reads after M depletion.                
 
As demonstrated in the table 4, the mitochondrial reads were less than 10% 
of the total, so I decided to continue removing all mitochondrial reads and, 
once obtained the final reads we had called the number of peaks which refer 
to effective number of accessible regions (Table 5). 
 
 Table 5 
Sample Peaks number 
Control-1 3113 
Tbx1-KD-1 26833 
Control -2 36615 
Tbx1-KD-2 50920 
 
Table 5. Total Peaks number in P19Cl6 cells. The table contain Sample and Peaks number 
(the overall chromatin accessible regions). 
 
Because of the large discrepancy between two different replicates, I decided 
to eliminate samples with low peak numbers. Peaks annotation and 
comparison with previously published ChIP-seq and RNA-seq data on the 
same cell line were performed using only one replicate for each condition: 
Control-2 and Tbx1-KD-2. Overall, I found 36615 chromatin accessible 
peaks in Control and 50916 accessible regions in Tbx1-KD cells. We 
evaluated the distribution of peaks, using ChIP-seeker (Yu G et al., 2015) 
relative to gene features defined as Promoter 1 to 3 kb (from 1 kb to 3kb from 
the transcription start site), 5’-UTR, 3’-UTR, First Exon, First Intron, Other 
Exon, Other Intron, Downstream, Distal Intergenic. In control sample 
33.45% of regions were localized around promoter, 49.61% were intragenic 
and 16.94% were distal intergenic while in the KD sample 31.48% of regions 
were localized around promoter, 49.14% were intragenic and 19.38% were 
distal intergenic. In both cases, peaks were distributed mostly at the promoter 
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regions of the genes and in the intragenic regions, as expected. Overall 
distribution suggested no differences in chromatin accessibility regions 
between the two different conditions. This first analysis revealed that 
technique was working well because a good percentage of chromatin 
accessibility were located around 3000 bp of TSS of genes. We have plotted 
two different graphs: Annotation Pie and Heatmap Profile (Fig. 18). 
 
Fig. 18 
 
 
 
 
Figure 18. Total accessible regions distribution in Control and Tbx1-KD P19Cl6 cells. 
Total accessible regions of Control (left), KD (right). On the top: Annotation pie shows 
accessible regions distribution around gene features. On the bottom: Heatmap shows 
accessible regions distribution around TSS (from 1kb to 3kb). 
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Intersection of ATAC-seq and ChIP-seq data: many TBX1 binding sites are 
located within closed chromatin. 
 
Overall, considering the all peaks there were no obvious differences between 
Control and Tbx1-KD sample. Next question that we want to answer was: 
Does Tbx1 bind opened or closed chromatin? In order to answer this 
question, I compared ATAC peaks with TBX1 binding sites obtained with 
the same cell line under the same conditions (Fulcoli FG et al., 2016). 
Specifically, I considered the highly statistically significant 2388 sites 
(“golden peaks”). Results indicate that TBX1 peaks are mostly located in 
ATAC-negative regions (closed chromatin), as only 335 of them (14%) 
overlap with ATAC peaks (Fig. 19). In addition, Tbx1-KD did not affect 
significantly chromatin accessibility in TBX1 binding sites: 450 regions 
(18.8% of TBX1-binding sites) were localized in open chromatin (Fig. 19). 
After KD, 28 TBX1 binding sites (1.4%) loose accessibility while 143 (6%) 
gain accessibility.  
 
Fig. 19 
 
 
Figure 19. Intersection between Control and Tbx1-KD accessible regions and TBX1-
binding regions in P19Cl6 cells. Venn diagram of Control (Left) and Tbx1-KD (Right). In 
Control, 14% of TBX1-binding regions (violet) overlap with accessible regions (blue). In 
Tbx1-KD, 18.8% of TBX1-binding regions (violet) overlap with overlap with accessible 
regions (blue). 
 
To confirm these results, I repeated the same comparison analysis between 
chromatin accessibility and TBX1-binding sites without using chromatin 
regions as “peaks” but by using the genome coverage for both conditions 
(Quinlan AR et al., 2010)  
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I have plotted the genome coverage distribution of accessible regions in 
Control and KD around the TBX1 binding sites. The figure 20 shows that 
there is no overlap or vicinity between TBX1 binding sites and chromatin 
accessible regions. 
 
Fig. 20 
 
 
Figure 20. Intersection between Control and Tbx1-KD accessible regions and TBX1-
binding regions based on genome coverage in P19Cl6 cells. Coverage distribution of 
accessible regions in Control (violet) and Tbx1-KD (light blue) around the TBX1 binding 
sites. The figure shows that there is no overlap or vicinity between TBX1 binding sites and 
accessible regions. Y-axis (Read count Per Million mapped reads), X-axis (Genomic 
Regions). 
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Many genomic regions which are not bound by TBX1 are affected by Tbx1 
loss of function. Although I found no effect of loss of Tbx1 at TBX1-binding 
regions, I noted that the number of peaks in the Tbx1-KD condition are 
higher than in the Control sample. Therefore, I performed a search of 
differentially accessible regions (DARs) using a method that takes into 
account the differences in the number of reads in different sample by 
performing normalization which, in ATAC experiments, because of the lack 
of input sample, taking into account a large window of background genome-
wide signal. DARs between Control and Tbx1-KD conditions was carried out 
using a tool: Spatial Clustering for Identification of ChIP-Enriched Regions 
(SICER) (Shiliyang X et al., 2014). SICER-df was used in order to evaluate 
common regions (Control and Tbx1-KD) which increase/decrease 
accessibility in KD cells and it works by calculating how many reads mapped 
within specific regions. Using this algorithm, I found 2401 regions that 
increase accessibility in KD cells, while I found only 16 regions that decrease 
accessibility. About 72% of these DARs were located in promoter regions (1 
kb from the transcription start site). In contrast, only 27.7% of the non DARs 
regions were located in promoters. In addition, only 1.4% (34) of TBX1 
binding sites overlap with DARs suggesting that TBX1 might not remodel 
these 2401 regions through DNA binding (Fig. 21). 
 
Fig. 21  
 
 
Figure 21. Intersection between differential accessible regions (DARs)/ Total Regions 
and TBX1-binding sites in P19Cl6 cells. On the left: intersection between Total Regions 
(Ctrl) localized for about 30% around promoter and TBX1-binding regions (only 14%). On 
the right: intersection between DARs localized for about 72% around promoter and TBX1-
binding regions (only 1.4%, less than Total Regions).  
 
Next, I asked whether DARs are characterized by the presence of specific 
transcription factors binding motifs. To this end, I have used Hypergeometric 
Optimization of Motif EnRichment (HOMER), a tool for motifs discovery 
(Heinz S et al., 2010). Results showed that there is no enrichment of T-box 
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binding motifs, confirming that does not bind these regions (Fig. 22). Instead, 
I found enrichment for other transcription factors listed in the figure 22. 
 
Fig. 22 
 
 
Figure 22. Motifs discovery in differential accessible regions (DARs) which increase 
accessibility in P19Cl6 Tbx1-KD cells. Known motifs (top) and De novo motifs (bottom) 
found no T-box sequences. The top scorer is NFY for both motifs categories. Figure is 
subdivided for Rank, Motif, P-value, Transcription factor (TF).  
 
Next, I asked how TBX1 may remodel these 2401 regions without binding to 
them. There are at least two possibilities: 1) Tbx1 may regulate transcription 
factor-encoding genes, and their product, in turn, may remodel chromatin; 2) 
Remodelling may be due to a DNA-independent effect of Tbx1. To address 
this possibility, we will test whether TBX1 immunoprecitated with some of 
the transcription factors listed in the Fig. 22. I will also determine if loss of 
Tbx1 increases the occupation of TFs like NF-Y to promoters.  
I have selected some putative responsive loci associated to DARs and I found 
no differences in chromatin accessibility associated to these loci following 
Tbx1 overexpression (Fig. 23). In future it could be interesting to select other 
putative responsive loci or maybe it could be necessary another approach to 
address this point.  
54 
 
Fig. 23 
 
 
Figure 23. Putative responsive loci associated to differential accessible regions (DARs) 
which increase accessibility in P19Cl6 Tbx1-KD cells. Enrichment of chromatin 
accessibility associated to Rtn3, Atp5e, Eef2k, Sesn2 found no differences following Tbx1 
overexpression. On the Y-axis there is a normalized expression value (2-ΔCt), on the X-axis 
there is EV (Empty Vector), WT (Tbx1 exogenous copy) and MUT (Tbx1 exogenous copy 
unable to bind DNA). D1 refers to differentiation point while Neg Ctrl refers to the threshold 
of closed chromatin: primers were built in a region that does not contain any genes in a range 
of about 80 kb. 
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Some loci show delayed response to loss of Tbx1 dosage in time-course 
experiments. 
 
The lack of a strong effect of TBX1 on chromatin remodelling is surprising, 
given the interactions with chromatin remodelling proteins reviewed in the 
introduction. Therefore, I have asked the question: Why TBX1 does not 
induce significant chromatin remodelling at its binding regions? I have 
considered two hypotheses to explain my results: 1) P19Cl6 cells may lack 
required cofactors that could help TBX1 in chromatin remodeling. Therefore, 
I have tested other model systems (see Chapter 3). 2) The chromatin response 
may not be evident at this time point of differentiation but may appear at a 
later stage because cofactors may become biologically available later. To 
address this second point, I have performed time-course experiment using Q-
ATAC instead of ATAC-seq, and tested chromatin access at specific loci. I 
have collected cells at three different time points during the differentiation 
protocol, T1 (13 hours after siRNA transfection), at D1 (24 hours after 5-Aza 
induction) and at D2 (24 hours after DMSO addition) and for each point two 
biological replicates were considered (Fig. 24). 
 
Fig. 24 
 
 
Figure 24. P19Cl6 cells differentiation until D2. The differentiation scheme starts from 
transfection point. 13 hours after transfection, cells were collected at T1. After 5 hours, cells 
were induced with 5-Aza and collected 24 hours later at D1. DMSO was added and after 24 
hours cells were collected (D2) (Fulcoli FG et al., 2016). 
 
P19Cl6 cells were treated with siRNA pools (targeted to Tbx1 or non-
targeted control) After 13 hours (hr) the first sample was collected T1, then 
after 5hr 5-Aza was added to the remaining cells and other sample was 
collected at after 24hr D1, and DMSO was added to the remaining cells. The 
third and last sample was collected after 24hr from DMSO exposure (D2) 
(Fulcoli FG et al., 2016). As we expected, Tbx1 was knocked down at all 
three time points, compared to controls (Fig. 25).  
56 
 
Fig. 25 
 
 
Figure 25. Tbx1-KD in P19Cl6 cells during differentiation. Tbx1 was reduced in KD 
sample (blue) compared to Control (orange) at all three time points. RQ expresses the 
normalized expression value.  
 
Once verified the Tbx1 expression levels in Control and KD conditions, 
tagmented chromatin for both replicates on 50000 cells were amplified, 
purified and then used for quantitative ATAC (Q-ATAC). For chromatin 
enrichment analyses were chosen loci bound by TBX1 that contain accessible 
regions. The loci selected were: Bai2 (encoding brain inhibitor of 
angiogenesis, a GPCR receptor of secretin), Cdc42bpg (protein tyrosine 
kinase), Brd4 (encoding serine/threonine kinase involved in chromatin 
remodelling), Pxn (encoding protein involved in focal adhesion), Dusp7 
(encoding phosphatases of threonine, tyrosine and serine). For real-time PCR, 
we have used both biological duplicates for each time point and each 
duplicate was divided in two technical replicates. We used two different 
controls: Gapdh promoter (positive control) representing the open chromatin, 
and a desert island locus (negative control) which does not contain any genes 
in a range of about 80 kb. The figure 26 illustrated the time-course 
enrichment (2-ΔCt). The dotted lines indicate the values of negative control 
regions Control (orange) and KD (blue) samples. 
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Fig. 26  
 
 
Figure 26. Putative responsive loci to Tbx1-KD in P19Cl6 cells. Enrichment of chromatin 
accessibility associated to Bai2, Cdc42bpg, Brd4, Pxn, Dusp7 found that the first three loci 
became accessible at D2, after 66 hours from Tbx1-KD. On the Y-axis there is a normalized 
expression value (2-ΔCt), on the X-axis there are three different time points (T1, D1, D2). 
Colours legend are illustrated in the figure. 
 
Results showed that 3 out 5 loci tested (Bai2, Cdc42bpg and Brd4) became 
accessible after 66 hours from Tbx1-KD suggesting a possible role in 
enhancer priming (Wang C et al., 2016). Next, I have tested the hypothesis 
that overexpression of Tbx1 may be associated with chromatin changes by 
displacing the nucleosome core (Luger K et al., 2012). Thus, I have designed 
a gain of function experiment to test chromatin response. The time-course 
gain of function experiment was performed under the same conditions 
described for the loss of function experiment but, I transfected cells with an 
expressing vector containings a Tbx1-3xHA cDNA or with a control, empty 
vector. Chromatin from harvested cells was tagmented and stored while I 
checked the transfection efficiency, as normalizer was used beta actin (Fig. 
27). 
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Fig. 27 
 
 
Figure 27. Tbx1-overexpression in P19Cl6 cells during differentiation. Tbx1 was 
overexpressed in Tbx1-3xHA at T1, D1, D2 (detected with Anti-HA tag). Empty Vector was 
used as negative control. Beta actin was used as normalizer. 
 
Subsequently, I have carried out Q-ATAC for 5 selected loci (Fig. 28) 
 
Fig. 28 
 
 
Figure 28. Putative responsive loci associated to Tbx1 overexpression in P19Cl6 cells. 
Enrichment of chromatin accessibility associated to Bai2, Cdc42bpg, Brd4, Pxn, Dusp7 
found no differences following Tbx1 overexpression. On the Y-axis there is a normalized 
expression value (2-ΔCt), on the X-axis there is T1, D1 and D2. Colours legend are illustrated 
in the figure. 
 
Results showed that none of the loci tested is affected by increased dosage of 
Tbx1. In the future, it would be of interest to perform ATAC-seq 
experiments, rather than Q-ATAC to obtain a global view of chromatin 
accessibility. 
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Chapter 3 
 
mESC differentiation and Tbx1 expression. 
 
I wanted to confirm the data obtained in P19Cl6 cells a using different model 
system. We selected murine embryonic stem cells (mESCs) because of their 
potential differentiation skills. These undifferentiated cells can be induced, 
using specific factors, to differentiate into cardiomyocytes (Keller G et al., 
2005). This protocol (described in details in the Materials and Methods 
section) can be divided in three parts: the first one is cell adhesion and 
proliferation, the second one is mesoderm induction and the last one is 
cardiac specification and maturation.  
We have analysed the expression markers involved in cardiomyocytes fate 
and differentiation and we found that cTnt2 was progressively expressed 
during differentiation, starting at day 4 and increasing up until day 10. Tbx1 
started to be expressed at day 4 (highest Tbx1 expression during 
differentiation) and was also expressed at day 10 (Fig. 29). 
 
Fig. 29 
 
 
Figure 29. Tbx1 and cTnt2 expression during murine embryonic stem cells (mESCs) 
differentiation. On the left: Tbx1 (239bp) expression at d0, d2, d4 (expressed), d6, d10 (low 
expressed). On the middle: cTnt2 (102bp) expression at d0, d2, d4 (low expressed), d6 
(expressed) d10 (high expressed). On the right: Gapdh (106bp) during the same 
differentiation used as normalizer. 
 
I have performed RNA-seq and ATAC-seq at day 2 and day 4. Results 
confirmed that Tbx1 is activated at day 4 but it is expressed at low level in 
this system. The data also showed that between day 2 and day 4 most genes 
encoding cardiogenic transcription factors are activated at day 4 (Table 6). 
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Table 6 
 
 
Table 6. Genes involved in cardiopharyngeal mesoderm during murine embryonic stem 
cells (mESCs) differentiation. The table is divided in Gene, d2_FPKM (the FPKM average 
of two biological duplicates), d4_FPKM (the FPKM average of two biological duplicates), 
d2->d4 (gene expression variations during d2-d4 differentiation; + refers to gene whose 
expression increases at day 4 while - refers to gene whose expression decreases at day 4).  
 
ATAC-seq signal between day 2 (d2) and day 4 (d4) has identified genes 
involved in cardiac differentiation: Smarcd3 essential for function of BAF 
chromatin remodelling complexes in heart development (Lickert H et al., 
2004), Gata4 important for cardiomyocytes stem cells differentiation and 
Mesp1, a key regulator of cardiovascular lineage commitment (Bondue A et 
al., 2010) (Fig. 30).  
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Fig. 30 
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Figure 30. Chromatin accessibility variations in genes involved in cardiac 
differentiation. Differential Enrichment of chromatin accessibility associated to Smarcd3 
(Top), Gata4 (middle), Mesp1 (bottom). On vertical axis there are the genome coverage of 
day 2 first replicate, day2 second replicate, day4 first replicate and day4 second replicate. 
Red arrow indicates the open chromatin open in day4 compared to day2. 
 
Some of the regions which show different chromatin accessibility at these 
two stages of differentiation are being validated. Although results with these 
experiments should allow the identification of enhancers involved in 
differentiation, the low expression levels of Tbx1 makes it difficult to 
attribute any chromatin change to Tbx1 gene activation. To enrich the cell 
population with Tbx1-expressing cells, the lab has carried out flow cytometry 
analyses followed by cell sorting, with standard surface markers: FLK1 and 
PDGFRa. We were able to isolate at day 4 (highest Tbx1 expression) three 
different subpopulations which are separated because of their surface 
markers. The first one was positive for PDGFRa, the second double positive 
for PDGFRa and FLK1 (also known as VEGFR2) and third one which was 
positive for FLK1. Cell populations of three subgroups were respectively 9%, 
68.2% and 21 % of the total (Fig. 31).  
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Fig. 31 
 
 
Figure 31. FACS-sorted murine embryonic stem cells (mESCs) differentiated at d4. 
FACS-sorted d4 identifies three distinct subpopulations: PDGFRa+, PDGFRa+/FLK1+, 
FLK1+. Cell populations were respectively 9%, 68.2% and 21% of the total. RNA was 
extracted from sorted cells of these three populations and we tested the expression of Tbx1. 
We found that at day 4 the highest expression was in the PDGFRa+; FLK1- subpopulation 
(Fig. 32). 
 
Fig. 32 
 
 
Figure 32. Tbx1 expression in murine embryonic stem cells (mESCs). Histogram showing 
Tbx1 expression (mRNA relative expression levels) in d4 total cells (pink), Pdgfra+ (red), 
Pdgfra+/Flk1+ (yellow), Flk1+ (blue) cells. Tbx1 is highly expressed in Pdgfra+ cells. 
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Therefore, we have chosen this specific subpopulation to understand how and 
if TBX1 is able to have an impact on chromatin accessibility. The laboratory 
has generated Tbx1-/- mESC using CRISPR-Cas9 gene targeting. I have used 
these cells to perform ATAC-seq and RNA-seq experiments along with WT 
cells at day 4, after sorting Pdgfra+; Flk1- cells. 
65 
 
Chromatin remodelling and gene expression in differentiated mESCs WT 
and Tbx1-/-. 
 
ATAC-seq and RNA-seq experiments were done on two biological replicates 
of mESCs (Tbx1 WT and KO) differentiated at day 4 and sorted for PDGFRa 
and FLK1. The overall number of accessible chromatin regions is illustrated 
in the table 7.  
 
Table 7 
Sample Peaks number 
d4-PDGFRa+_WT-1 4101 
d4-PDGFRa+_KO-1 10305 
d4-PDGFRa+_WT-2 8228 
d4-PDGFRa+_KO-2 4115 
 
Table 7: Total Peaks number in d4-PDGFRa+, Tbx1 WT and KO murine embryonic 
stem cells (mESCs). Table is divided in Sample and Peaks number (total accessible 
chromatin regions). 
 
The number of peaks in d4-PDGFRa+-WT-1 and d4-PDGFRa+-KO-2 was 
very low, so we decided to pool replicates for both conditions. Table 8 shows 
number of pooled peaks. 
 
 Table 8 
Sample Pooled Peaks number 
d4-PDGFRa+-WT_pooled 12109 
d4-PDGFRa+-KO_pooled 14443 
 
Table 8: Total pooled Peaks number in d4-PDGFRa+, Tbx1 WT and KO murine 
embryonic stem cells (mESCs). Table is divided in Sample and Pooled Peaks number (total 
accessible chromatin regions). 
 
Next, we annotated peaks using ChIP-seeker and we found that overall peaks 
distribution was similar between WT and mutant cells. ATAC-seq peaks 
were located around the transcription start site (TSS) of genes (Fig. 33). 
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Fig. 33 
 
 
Figure 33. Total accessible regions distribution in d4-PDGFRa+, Tbx1 WT and KO 
murine embryonic stem cells (mESC). Heat map of chromatin accessible regions 
distribution around TSS (from 1kb to 3kb) of WT (Left) and KO (Right). 
 
There is no map of TBX1 binding sites in mESCs, and there are no longer 
antibodies suitable for TBX1 ChIP experiments. Therefore, we cannot 
establish whether TBX1 remodels chromatin at its binding sites. Thus, I have 
limited my studies to the identification of differentially accessible regions 
(DARs) following by Tbx1 dosage variations and analysis of RNA-seq data. I 
analysed DARs which taking into account all common regions between two 
different conditions with a differentially enrichment. I found 48 regions that 
decrease accessibility in KO and 117 regions that increase accessibility in the 
same condition. Suddenly I noted that, also for this model system when Tbx1 
was absent, the number of differential accessible regions increased and were 
distributed around TSS and promoter of genes as expected. Started from 
these 117 regions, I obtained a list of associated genes that we compared with 
differentially expressed genes between Tbx1 WT and KO. I generated the 
table 9 divided in different fields: log2FC which measures how many genes 
were differentially expressed between both conditions, P-value, the Gene 
name, the ATAC ratio which expresses the ratio between normalized reads of 
both conditions, and gene annotation. Two accessible regions, associated to 
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Mycl and Robo2 were localized around promoters while other six regions 
were localized in intra/inter genic features. We are going to validate some of 
these genes “in vivo” using a model system in which Tbx1 expression could 
be monitored and studied; one is very interesting: Cyp26a a known Tbx1 
marker (Caterino M et al., 2009). Cyp26a1, gene required for retinoic acid 
inactivation during embryogenesis, is a potential Tbx1 target from a 
microarray screen comparing wild-type and null Tbx1 mouse embryo 
pharyngeal arches (PA) at E9.5 (Roberts C et al., 2006).  
 
Table 9  
 
 
Table 9: Common genes associated to differentially accessible regions (DARs) and 
differentially expressed (DE) genes in d4-PDGFRa+, Tbx1 WT and KO murine 
embryonic stem cells (mESCs). The table is divided in Gene Symbol, log2FC (measures 
how many genes were differentially expressed between both conditions), P-value, Gene 
Name, ATAC ratio KO/WT (expresses the ratio between normalized reads of both 
conditions), and gene annotation. 
 
Although P19Cl6 showed that there was no chromatin accessibility where 
TBX1 binds chromatin, in this cells we found a list of Motifs statistically 
significant and most of them were bound by T-box transcription factors. (Fig. 
34). 
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Fig. 34 
 
 
Figure 34. Motifs discovery in d4-PDGFRa+ differential accessible regions (DARs) 
which increase accessibility in murine embryonic stem cells (mESCs) Tbx1-KO cells. 
Motifs found many T-box sequence. Figure is subdivided for Rank, Motif, Name of 
transcription factors and P-value.  
 
Next I have focused on regions which gain or lose accessibility following by 
Tbx1 dosage variations, they showed a distinct pattern around gene features 
compared to total accessible regions. The regions which gain or lose 
accessibility refers to regions which are unique in one specific condition 
different from DARs which refers to all common regions between two 
conditions with differentially enrichment. This analysis may take with 
caution because data were not normalized. Also in this context, in the 
accessible regions where Tbx1 was absent I found significant T-box motif 
including EOMES, TBX21, TBX2, TBET, TBX20, TBX1, TBX4 (Fig. 35). 
 
Fig. 35 
 
 
Figure 35. Motifs discovery in regions which gain accessibility in d4-PDGFRa+ murine 
embryonic stem cells (mESCs) Tbx1-KO cells. Motifs analyses found a T-box sequence 
highly significant. Figure is subdivided for Rank, Motif, and P-value. In red arrow are 
highlighted T-box Transcription Factors: EOMES, TBX5, TBX2, TBET, TBX20, TBX1, 
TBX4, TBX21. 
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I uploaded on UCSC genome browser the T-box bound motifs and I noted a 
peak upstream Rpf1 gene (Fig. 36). This region, as an example, was opened 
in Tbx1 KO cells and closed in WT cells, suggesting that TBX1, or other T-
box transcription factors, may limit access to the chromatin. 
 
Fig. 36 
 
 
Figure 36. T-box motif in regions which gain accessibility in d4-PDGFRa+ murine 
embryonic stem cells (mESCs) Tbx1-KO cells. Genome coverage identifies a T-box motif 
(Motif_Tbox), upstream to Rpf1, in Tbx1 KO cells compared to WT cells suggesting that T-
box Transcription Factor may limit access to the chromatin. 
 
Gene expression analyses of WT vs KO samples resulted in good quality data 
and good reproducibility among replicates (Fig. 37). 
 
Fig. 37 
 
 
Figure 37. RNA-seq data on d4-PDGFRa+, Tbx1 WT and KO murine embryonic stem 
cells (mESCs). Heat Map showing a good reproducibility between independent biological 
duplicates WT and KO. Colour Key indicates the gene expression, red (high), green (low). 
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I have determined differentially expressed (DE) genes using DeSeq2 
algorithm (Love Mi et al., 2014). I found 642 DE genes of which 230 are up 
regulated and 412 are down regulated. DE genes were analysed for Gene 
Ontology (GO) terms using DAVID (Huang DW et al., 2009). Results (Table 
10) showed terms “enrichment” relative to pathways in which Tbx1 has 
already been shown to play a role; for example, “heart development”, “heart 
morphogenesis” etc. 
 
Table 10 
 
 
Table 10: Differentially expressed (DE) genes between d4-PDGFRa+, Tbx1 WT and KO 
murine embryonic stem cells (mESCs). Term indicates the biological process; P-value 
indicates the significant TERM. In red there are some interesting biological processes: heart 
development, angiogenesis, heart morphogenesis. 
 
Overall, the experiments performed in Tbx1 WT and mutant mESCs provide 
a good level of confidence that this is a useful model for further studies. In 
addition, chromatin remodelling data essentially confirm the P19Cl6 data 
showing that loss of Tbx1 is associated with gain of accessibility in discrete 
loci. However, in contrast to P19Cl6 data, mESC DARs were enriched in T-
box binding sites, leaving open the possibility that TBX1 may be directly 
responsible for chromatin remodelling. A map of TBX1 binding sites in this 
model will be necessary to confirm this possibility. 
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Chromatin remodelling studies in vivo: Initial experiments and future 
perspectives. 
 
It is desirable to replicate what we have obtained in the cell system using an 
“in vivo” approach. Thanks to the use of different cell types, we were able to 
demonstrate that there was chromatin remodelling due to Tbx1 dosage 
variations. In the last period of Ph.D. program, I moved from cells to 
embryos in order to demonstrate that there are chromatin changes following 
loss of Tbx1 expression also in vivo. We initiated ATAC-seq on FACS-
purified cells from Tbx1 heterozygous and homozygous embryos. To label 
Tbx1-expressing cells we are crossing Tbx1cre/+ mice with Tbx1flox/+; R26mT/mG 
mice to obtain Tbx1cre/+ and Tbx1cre/flox embryos. The results are GFP+ cells 
which can be Tbx1cre/+ (Tbx1 heterozygous) or Tbx1cre/flox (Tbx1 
homozygous). Figure 38 shows an example of GFP+ cells in a Tbx1cre/+; 
R26mT/mG E9.5 mouse embryo section. 
 
Fig. 38 
 
 
Figure 38. Tbx1 expression in Tbx1cre/+; R26mT/mG embryo. GFP+ cells mark the Tbx1 
expression domain in E9.5 embryo. 
 
Embryos are harvested at E9.5 (stage selected because this is a critical point 
for Tbx1 function), disaggregated and subjected to FACS purification of 
GFP+ cells. At the moment, we obtained two good libraries for two different 
Tbx1cre/flox; R26mT/mG embryos: profiles of DNA fragment are distributed 
between 200bp to 600 bp and we have selected, at moment, both embryos 
with 19 somites (Fig. 39). At this point we have two biological replicates for 
Tbx1 homozygous condition, we are waiting for two heterozygous mice for 
sequencing.  
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Fig. 39 
 
 
Figure 39. DNA size distribution in Tbx1cre/flox; R26mT/mG embryos. The figure shows the 
DNA size distribution between 100bp to 600bp. 1 and 2 refers to first and second replicate 
and blue arrows indicate the fragments more abundant than others. 
 
These two libraries will be paired with other two libraries of Tbx1 
heterozygous mice to complete one run sequencing. ATAC-seq results will 
give us information regarding the chromatin accessible distribution following 
by Tbx1 dosage variations. These data will be combined with data from 
Morrow lab that is collaborating with us and generating TBX1 ChIP-seq data 
using a new mouse line carrying a tagged isoform of the Tbx1 gene. 
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DISCUSSION 
 
Tbx1 is a candidate gene of DiGeorge syndrome and is necessary for outflow 
tract and craniofacial muscles development. In the last 20 years, different 
scientists have been focusing on this gene and many genetic experiments in 
mouse models have established that Tbx1 is a major regulator of the 
development of the cardiopharyngeal mesoderm. Although many epigenetic 
approaches have been pursued, the many details of the molecular 
mechanisms by which Tbx1 functions remain to be elucidated. The principal 
aim of this work thesis is to determine mechanisms of chromatin interactions 
by which Tbx1 regulates target genes. Tbx1 encodes a protein that belongs to 
T-box transcription factor family, which is essential for many development 
processes. Indeed, several T-box genes are haploinsufficient in a large 
number of birth defects (Naiche LA et al., 2005). Research in molecular 
mechanisms have been hampered by the embryonic lethality associated with 
T-box deficiency in mice, leading to difficulties in finding target genes 
(Miller S et al., 2009). Recently, many studies have been focusing on the 
interactions of T-box proteins with the histone modifying machinery. It 
seems that T-box factors cooperate with histone modifying enzymes such as, 
histone acetyltransferases or deacetylases and methyltransferases or 
demethylases in order to modulate the expression of target genes. For 
example, T-BET interacts with both H3K27-demethylase and H3K4-
methyltransferase activities. It was found that this correlation between T-box 
and histone modifiers activities is associated with conserved residues in the 
T-box DNA binding domain provided the potential that this is a common 
mechanism utilized by the T-box family to regulate epigenetic states at 
development transition (Miller S et al., 2009). Fulcoli and co-workers 
(Fulcoli FG et al., 2016) found that TBX1, through interaction with a histone 
methyltransferase MLL3, promotes H3K4me1-regions and it binds to 
H3K27Ac-poor regions (Fulcoli FG et al., 2016) but the mechanism is still 
unclear. In the first period of my PhD program, I have tried to understand 
better this inverse correlation between TBX1 and histone acetylation. 
Through cells manipulation, I have done a ChIP-seq experiment using 
H3K27Ac antibody, following by Tbx1 dosage variations in order to 
understand if it could be differences in the genome-wide acetylation levels. 
ChIP experiment was abandoned because we had many technical problems 
related to sequencing. Although genome-wide acetylation maps following by 
Tbx1 dosage variations were not available, I demonstrated, using another cell 
system, in one specific case, that Tbx1 repression of Mef2c gene expression is 
correlated with the de-acetylation of a specific enhancer named Anterior 
Heart Field (AHF) of the Mef2c gene (Pane LS et al., 2018). The mechanism 
has not been elucidated yet. We have done many co-immunoprecipitation 
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experiments between TBX1 and HDAC proteins (HDAC1 and HDAC2) and 
it seems that TBX1 does not interact with any of them. Of course, there are 
other HDACs that may interact with TBX1, and is also possible that the 
interaction is indirect so that it may not be revealed by a standard 
immunoprecipitation experiment. Furthermore, TBX1 might cause 
hypoacetylation by interfering with acetyltransferases rather than recruiting 
HDACs. Thus, further experiments are required to establish the mechanisms 
by which TBX1 binds H3K27Ac-poor regions. Histone post-translational 
modifications are not the only mechanism that TBX1 uses to regulate target 
genes because interaction with chromatin remodelers may be also important. 
TBX1 recruits BAF60a and activate or enhance transcription of a specific 
target (Chen L et al., 2012). Because the main function of chromatin 
remodelers is to make DNA more or less accessible to transcription factors 
and to the transcriptional machinery, I have focused on a newly developed 
and powerful technology to map chromatin accessibility genome-wide 
ATAC-seq. By manipulating the cell systems used in this work, I was able to 
generate maps of accessible regions with different dosages of Tbx1. I found 
that 86% of TBX1 binding sites are in closed chromatin. These regions do 
not remodel after 42 hours of TBX1 knock down. Differentially accessible 
regions (DARs) were mostly localized at the promoter of genes, and in 
regions that do not bind TBX1. Consistently, motif discovery analyses found 
no enrichment of T-box binding motifs in DARs. Therefore, TBX1 may 
remodel these regions, a) Indirectly or b) through a DNA-binding 
independent function.  
Concerning the possible indirect effect, Tbx1 may regulate transcription factor-
encoding genes, and their product, in turn, may remodel chromatin. A DNA-
binding independent function is also possible as there are precedents in the 
literature for TBX1 and for at least another T-box protein (Messenger NJ et al., 
2005). To demonstrate that TBX1 can remodel chromatin without binding 
DNA it would be necessary to test a mutant isoform unable to bind DNA. I 
have attempted to perform this experiment, but only using transfection of the 
mutant isoform compared to transfection of a WT expression vector. 
Unfortunately, the latter did not cause any chromatin remodelling at selected 
loci. There are different reasons that could explain why in these loci I did not 
find any differences in chromatin accessibility. DARs were detected after Tbx1 
loss of function and these loci may not be responsive to overexpression. 
Furthermore, DARs have not been validated yet with additional experiments, 
therefore, it will be necessary to select validate loci for gain of function 
experiment. HOMER analyses of DARs in P19Cl6 cells returned strong 
enrichment of a particular transcription factor, NF-Y.  
NF-Y is a pioneer factor which promotes chromatin accessibility by 
displacement of nucleosome core (Oldfield AJ et al., 2014). We will test 
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whether TBX1 knock down increases NF-Y occupancy at selected loci. If this 
is the case, we will test whether TBX1 may directly interact with this pioneer 
factor and perhaps make it less biologically available.  
Next, we asked why TBX1 does not induce significant chromatin remodelling 
at its binding regions? 
The results of my time course-experiment suggest that chromatin remodelling 
may occur at a later time point, perhaps because additional, required co-factors 
may only become available later during differentiation. Another, but related 
reason as to why we do not see remodelling at TBX1 binding sites, may be that 
P19Cl6 cells may not express co-factors required for chromatin remodelling. 
For this reason, I have also used mESC cells to study chromatin remodelling, 
and I am planning to use also an in vivo model, with the caveat that a map of 
TBX1 binding sites in these systems is not yet available.  
An overall comparison of P19Cl6 and mES cell-derived data reveals 
differences and communalities. The main difference is that HOMER analyses 
of DARs produced substantially different lists of binding motifs, it seems that 
in P19Cl6 cells T-box factors do not bind any DARs suggesting an indirectly 
or DNA-binding independent mechanism. The finding of T-Box motifs 
enrichment in DARs and in regions which increase accessibility in KO 
condition of mESC model suggest that a good portion of chromatin changes 
may be located in TBX1-binding regions. Unfortunately, at the moment, we 
lack a good Tbx1 antibody necessary to depict the TBX1-binding regions in 
this cell system, therefore we cannot compare the accessibility regions with 
TBX1-binding sites. The hypothetical relation between T-box and regions 
which increase accessibility in KO condition remains a bioinformatics 
approach that certainly needs further investigations. The communality is that 
reduction or loss of TBX1 is associated with increased chromatin accessibility 
in both systems, suggesting that TBX1 suppresses chromatin accessibility at 
many loci. Figure 40 shows a working model by which TBX1 may regulate 
target genes. This could be a mechanism by which TBX1 inhibits cell 
differentiation in certain context such as cardiomyocyte differentiation. 
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Fig. 40 
 
 
Figure 40. Cartoon showing a working model by which TBX1 may regulate target 
genes. On the top, there is a schematic view of TBX1 working model: TBX1 (blue dot) can 
interact with Histone methyltransferases (HMTs – dark yellow dot) and tissue specific 
transcription factor (tsTF – green dot) and promotes the monomethylation of lysine 4 
(H3K4me1) TBX1 binds closed chromatin. Without TBX1, the chromatin may change 
conformation (closed-opened) and gene target transcription can start: RNA pol II (yellow 
dot) binds promoter (blue rectangle). H3K27Ac (violet dot) is a marker of active enhancer. 
At the bottom, there are three putative mechanisms. 1) Indirect effect: TBX1 (blue dot) may 
regulate transcription factors-encoding genes (red rectangle), and their product (TFx – 
orange dot), in turn, may remodel chromatin. 2) DNA-binding independent effect: TBX1 
(blue dot) interact with TFx (orange dot) or other proteins outside from chromatin context 
and, with a mechanism not yet demonstrated, the chromatin may change accessibility. 3) 
Repressor effect: Without TBX1 (blue dot), enhancers (black rectangle) may be active 
(H3K27Ac in violet) and RNA pol II (yellow dot) promotes transcription. By the contrast, 
TBX1 interacts with another TBX1 (blue dots) and repress transcription by masking 
enhancer (black rectangle) region.  
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CONCLUSIONS 
 
Altogether, my results indicate that TBX1, a candidate gene of DiGeorge 
syndrome necessary plays important roles in gene regulation. Although 
TBX1 was identified about twenty years ago, its molecular functions are still 
to be clarified. In this work thesis I have demonstrated that TBX1 function 
may be cell type and context dependent. In P19Cl6 cells, TBX1 binds closed 
chromatin, and its loss of function increases chromatin accessibility in 
regions that are not bound by TBX1. This effect may occur through an 
indirect mechanism or through a non-DNA binding mechanism. Data that I 
have obtained using differentiating murine embryonic stem cells (mESCs) 
confirm that loss TBX1 opens chromatin. However, in these cells, I did find 
in opened regions, T-box binding motifs, albeit by bioinformatics analysis. 
These data suggest that TBX1 works differently in different cell types, 
perhaps because of the availability of different cofactors. However, 
bioinformatics finding need to be validated, therefore in the last period of my 
PhD program, I am using mESCs in which a specific tag (V5) has been 
knocked-into the Tbx1 locus and use anti-tag antibodies for ChIP-seq 
analysis. The epigenomic approach used in this work revealed new, 
unexpected findings concerning the chromatin response to TBX1 dosage, and 
open a new perspective onto the molecular functions of this transcription 
factor. 
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